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Summary 
 
The cell-cell and cell-matrix adhesion molecule CD44 and its numerous splice 
variants are involved in a multitude of physiological and pathological processes, including 
tumour progression. Especially variant CD44 has been implicated in metastasis formation.  
For long term in vivo experiments on metastasis formation, a plasmid based RNAi 
technique was applied to generate stable splice variant ‘v7’-specific CD44 knock-down 
clones of a highly metastatic rat pancreatic adenocarcinoma cell line (BSp73ASML). The 
resulting phenotype was characterized with an emphasis on interactions of CD44v with the 
tumour surrounding during the course of metastasis formation. Loss of CD44v is 
accompanied in vivo by a marked reduction in metastatic growth in the lymph nodes and 
particularly in the lung, which could be reverted by restoring CD44v expression in the knock-
down cells. The impaired metastatic growth was not due to a lower proliferative activity or a 
reduced anchorage-independence of these cells in vitro. Instead, they display several defects, 
which can be attributed to perturbed interactions of CD44v with the microenvironment. 
Compared to ASMLwt cells CD44vk.d. cells do not form cell aggregates in stromal 
surroundings, such as lymph nodes and the lung, due to lost cell-cell adhesion, mediated by 
interactions of CD44v and hyaluronic acid (HA). Furthermore, CD44vk.d. cells exhibit an 
impaired matrix production, as CD44v is most likely involved in the assembly of matrix 
components, containing HA, collagen and laminin. The matrix supports rapid adhesion of 
ASML cells through β1 integrin and in addition contributes to survival. Finally, the loss of 
CD44v is accompanied by a marked decrease in apoptosis resistance. Impaired PI3K-Akt 
survival signalling, activated by CD44v was identified as the cause of this defect.  
In conclusion, CD44v contributes to the metastatic phenotype of ASML cells as a 
multifunctional player interacting with the surrounding in several ways. First, as cell-cell 
adhesion molecule by mediating cell aggregation, second, as cell-matrix adhesion molecule 
by organizing matrix generation and last, as signalling molecule supporting survival. This 
highlights the role of variant CD44 in the metastatic spread of tumour cells through complex 
interactions with the tumour microenvironment and underlines the important role of a highly 
regulated interplay between tumour cells and their surrounding for metastasis formation.  
Zusammenfassung 
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Zusammenfassung 
 
 Das Zell-Zell und Zell-Matrix Adhäsionsmolekül CD44, sowie seine zahlreichen 
Spleißvarianten sind an einer Vielzahl physiologischer und pathologischer Prozesse beteiligt, 
zu denen auch die Tumorprogression zählt. Besonders variante CD44 Formen wurden mit 
Metastasierung in Verbindung gebracht.  
 Um langwierige in vivo Experimente zur Untersuchung von Metastasenausbildung zu 
ermöglichen, wurden stabile CD44-‘knock-down’-Klone einer stark metastasierenden 
Pankreas-Adenokarzinomlinie der Ratte (BSp73ASML) generiert. Über plasmidbasierte 
‘RNA interference’ (RNAi) wurde die CD44-Expression spleißvarianten-‘v7’-spezifisch 
reguliert. Der resultierende Phänotyp wurde besonders im Hinblick auf Interaktionen 
zwischen CD44v und der Mikroumgebung im Verlauf der Metastasierung charakterisiert. In 
vivo führt der Verlust von CD44v zu deutlich reduzierter Metastasenbildung in den 
Lymphknoten und besonders in der Lunge, und dieser Effekt war durch wiederhergestellte 
CD44v-Expression in den ‘knock-down’-Zellen wieder umkehrbar. In vitro zeigen die 
CD44v-k.d.-Zellen unveränderte Proliferationsaktivität und das gleiche 
verankerungsunabhängige Wachstumsvermögen wie der Wiltyp. Demgegenüber weisen sie 
mehrere Defekte auf, die auf Interaktionsverlust von CD44v mit der Mikroumgebung 
beruhen. In stromaler Umgebung, wie in den Lymphknoten und der Lunge, bilden CD44v-
k.d.-Zellen im Gegensatz zu ASMLwt-Zellen keine Zellaggregate aus, was auf den Verlust 
von CD44 und Hyaluronsäure vermittelten Zell-Zell-Kontakten zurückgeführt werden 
konnte. Zusätzlich ist die Matrixproduktion dieser Zellen beeinträchtigt, da CD44v höchst 
wahrscheinlich eine Rolle bei der ‘Matrixmontage’ zukommt. Als Bestandteile der Matrix 
konnten Hyaluronsäure, sowie Laminin und Kollagen identifiziert werden. Die Matrix 
ermöglicht ASML-Zellen eine rasche über β1-Integrin vermittelte Adhäsion und trägt 
darüberhinaus zum Überleben der Zellen bei. Schließlich geht der Verlust von CD44v mit 
einer deutlichen Abnahme der Apoptoseresistenz einher. Als Ursache für diesen Defekt 
konnte eine beeinträchtigte PI3K-Akt-Signaltransduktion identifiziert werden, die durch 
CD44v aktiviert wird.  
 Zusammenfassend konnte gezeigt werden, daß variantes CD44 maßgeblich zum 
metastasierenden Phänotyp von ASML Zellen als multifunktionales Molekül beiträgt, indem 
es mit der Mikroumgebung auf verschiedene Art und Weise interagiert. Zunächst als Zell-
Zell Adhäsionsmolekül, das Zellaggregation vermittelt, dann als Zell-Matrix 
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Adhäsionsmolekül, das die Bildung der Matrix organisiert, und schließlich als 
Signaltransduktionsmolekül, das zum Überleben der Zelle beiträgt. Diese Ergebnisse heben 
die Rolle von variantem CD44 für die Metastasenbildung von Krebszellen durch komplexe 
Interaktionen mit der Tumor-Mikroumgebung hervor und unterstreichen die entscheidende 
Bedeutung von komplex regulierten Wechselwirkungen zwischen Tumorzellen und ihrer 
direkten Umgebung für die Metastasierung.  
 
 
 
Introduction 
 4 
 
1.  Introduction 
 
 
30 years of intensive research in the field of tumour biology produced a huge body of 
knowledge and the basic mechanisms underlying the onset and progression of cancer have 
been identified. Nonetheless, after cardiovascular diseases cancer is still the 2nd leading cause 
of death in the western world (WHO, 2003).   
Cancer arises from a single cell that underwent genomic alterations leading to gain-
of-function of so called oncogenes or loss-of-function of tumour suppressor genes enabling 
uncontrolled growth and evading the bodies defence system to eliminate cells with 
dysfunctions. Our understanding of the mechanisms underlying early tumour progression is 
steadily growing, concomitantly with remarkable advances in the diagnosis and treatment of 
early tumours. However, there is still little understanding of the late steps in tumour 
progression leading to metastasis formation, which causes 90% of human cancer deaths 
(Storm, 1996). Although there is a growing number of genes being identified to take part, the 
underlying mechanisms that enable cancer cells to disseminate from the primary tumour mass 
and settle at distant sites in the body to form metastases is still poorly understood and deeper 
insights are needed for future therapeutic strategies to treat metastatic cancers.  
 
1.1  Cancer evolves as a multistep process 
 
During tumourigenesis the transformation of a normal cell into a malignant cancer 
follows a multistep process, which can be understood as an evolutionary event following the 
Darwinian concept. In order to develop into a life threatening invasive tumour a cell has to 
acquire certain characteristics, reflecting genetic alterations, which confer a growth 
advantage and drive the progressive transformation of the cell (Foulds, 1954; Nowell, 1976). 
Hanahan and Weinberg proposed six essential capabilities required for metastatic cancer 
formation (Hanahan and Weinberg, 2000), namely self sufficiency in growth signals, 
insensitivity to antigrowth signals, evasion of programmed cell death (apoptosis), limitless 
replicative potential, sustained angiogenesis and tissue invasion and metastasis.  
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Self sufficiency in growth signals 
Normal cells need growth stimuli in order to proliferate. These signals can be 
diffusible growth factors, extracellular matrix components or cell-cell stimulations. Usually 
secreted by other cell types (heterotypic signalling) these signals are sensed mainly by 
transmembrane receptors (binding to diffusible growth factors) and integrins (binding to 
components of the ECM), which translate the outside stimulus into an inside signal. Many 
cancer cell lines are independent on such exogenous growth stimulation because the activity 
of oncogenes mimics these growth signals by modulating the underlying stimulatory 
machinery at different levels. Tumour cells can either secrete their own growth factors 
(autocrine stimulation) or modify the corresponding signals within the cell, by modulating the 
receptors itself or the downstream signalling circuits. Alteration of growth factor receptor 
signalling can be achieved at the expression level leading to hyper-responsiveness to a given 
extracellular signal or by modulation of the signalling ability of the receptor, like expressing 
constitutively active versions of the receptor. A prominent example for this is the truncated 
version of the EGF-receptor (Fedi, 1997). Alternatively, the underlying growth signalling 
circuits itself can be modulated. The Ras-Raf-MAP kinase pathway for example is altered in 
25% of human tumours leading to mitogenic signals without ongoing upstream stimulation 
(Medema and Bos, 1993). Cells are also dependent on growth stimuli from the underlying 
ECM. Many cell-matrix interactions are regulated by integrins, which are heterodimeric cell 
surface adhesion molecules composed of one α and one β subunit. To date, 18 different α 
and 8 different β subunits have been identified, which form at least 24 heterodimers with 
different characteristics (Hynes, 2002; Shimaoka and Springer, 2003). Cancer cells can 
change their integrin repertoire by varying the combination of α and β subunits, for instance 
to favour expression to integrins eliciting progrowth signals at the expense of integrins with 
antiproliferative effects. In addition to this enhanced autonomy from their surrounding, 
tumour cells are able to modulate the behaviour of their neighbourhood for their own benefit. 
For example cancer cells can induce excess release of growth factors by neighbouring cells 
(Skobe and Fusenig, 1998) or stimulate inflammatory cells that should rather eliminate 
tumour cells, to promote their growth instead (Cordon-Cardo and Prives, 1999; Coussens et 
al., 1999; Hudson et al., 1999).  
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Insensitivity to antigrowth signals 
Just as normal cells display dependence on progrowth signals they are sensitive to 
antigrowth signals. This ensures tissue homeostasis and cellular quiescence. Antiproliferative 
signals can, like their positively acting counterparts, be soluble growth inhibitors and 
immobilized inhibitors present in the ECM or on neighbouring cells that are sensed by 
transmembrane receptors. Such inhibitory stimuli may lead to cell cycle arrest or induce a 
permanent mitotic stop by driving the differentiation of the cell. Most antiproliferative signals 
are relayed via the ‘retinoblastoma protein’ (pRb) pathway. PRb is a classical tumour 
suppressor gene, which controls progression from G1 to S phase of the cell cycle (Weinberg, 
1995). Cancer cells often fail to respond properly to antigrowth signals due to disruption of 
this pathway. Inactivation of the pRb protein leads to cell cycle arrest, either by mutation of 
the gene itself or by interfering with ‘transforming growth factor β’ (TGFβ) signalling, which 
normally blocks phosphorylation and thereby inactivation of pRb (Hannon and Beach, 1994; 
Datto et al., 1997). Blocking TGFβ signalling is achieved by cancer cells through down-
regulation of the corresponding receptor, by expression of dysfunctional receptors (Fynan 
and Reiss, 1993; Markowitz et al., 1995) or by modulating downstream signalling events 
(Schutte et al., 1996; Chin et al., 1998). Integrins can elicit antigrowth signals as well, and 
their expression pattern exerting proliferative or antiproliferative effects can be modulated as 
described above. Another way to avoid growth arrest is to circumvent differentiation. For 
example, antagonizing c-Myc function can lead to cellular differentiation (Dang et al., 1999) 
and recently a role for pRb in this context was shown as well (Goodrich, 2006).   
 
Evading apoptosis  
The third aspect limiting the expansion of a cell population is controlled by cross talk 
between the cell and the environment, deciding if a cell should live or die. Programmed cell 
death or apoptosis is the major event regulating this subject and it is evident that resistance to 
apoptosis is a key feature of cancer cells and for metastasis formation. Programmed cell death 
is a mechanism common in virtually all cell types and follows the same routes once it is 
induced by a variety of different triggers. Cell membranes are disrupted, the cytoskeleton and 
chromosomes are degraded and the cell usually dies within 24 hours (Wyllie et al., 1980). 
Apoptosis can be induced via two distinct routes, depending on the source of the apoptotic 
stimulus. The extrinsic or death receptor pathway is induced by surface receptors like Fas and 
‘tumour necrosis factor receptor’ (TNFR) that bind their corresponding ligands and induce a 
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cellular signalling cascade eventually leading to apoptosis. On the other hand there are 
several intracellular sensors detecting abnormalities within the cell, such as DNA damage, 
survival factor insufficiency or other stress signals like hypoxia (Evan and Littlewood, 1998). 
Such triggers induce the intrinsic or mitochondrial pathway, usually by activating pro- or 
inhibiting antiapoptotic members of the Bcl-2 protein family. These signals lead to 
breakdown of the mitochondrial membrane potential, release of cytochrome c and finally to 
apoptosis (Green and Reed, 1998). The p53 tumour suppressor gene for example, which is 
inactivated in more than 50% of human cancers, exerts its apoptotic effects via the intrinsic 
pathway. In response to DNA damage p53 upregulates the proapoptotic Bcl-2 protein Bax, 
which leads to cytochrome c release from the mitochondria (Harris, 1996). Both the external 
and intrinsic pathway finally converge on the ultimate effectors of apoptosis, intracellular 
proteases called caspases (Thornberry and Lazebnik, 1998). Two initiator caspases 8 and 9 
are activated either by death receptor signalling or by cytochrome c release, which then in 
turn activate several effector caspases, executing downstream steps of the apoptotic program 
and eventually leading to degradation of cellular structures, organelles and the genomic 
material (Fig. 1).  
 
Fig.1: The two main death pathways of apoptosis 
Death receptors on the surface of the cell bind their cognate ligands, leading to engagement of the 
‘death inducing signalling complex’ (DISC) and to activation of caspase 8. Internal stimuli, such as 
genotoxic stress induce apoptotic molecules, finally leading to inhibition of antiapoptotic molecules 
of the Bcl-2 family, subsequent cytochrome c release from the mitochondria and caspase 9 activation. 
Ultimately, both routes lead to activation of effector caspases and cell death. IAP inhibitor of 
apoptosis proteins. Adapted by permission from Macmillan Publishers Ltd: Nature Reviews Cancer 
(Mehlen and Puisieux., 2006).  
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Cancer cells escape from apoptosis either by deregulating the expression of death 
receptors on their surface or by survival signals, counteracting apoptotic stimuli through 
induction of antiapoptotic molecules. One of the best-studied pathways in this regard is the 
PI3kinase-Akt pathway. PI3K-Akt can be influenced by external stimuli, for example IGF or 
IL-3 (Evan and Littlewood, 1998), or by intracellular signals, e.g. the ras oncogene pathway 
(Downward, 1998) or the loss of the tumour suppressor pTEN, which normally attenuates 
Akt survival signals (Cantley and Neel, 1999). Likewise, cell-cell and cell-matrix interactions 
are necessary for cell survival. Apoptosis due to loss of adhesion to the substratum is called 
anoikis and provides another important mechanism to control cellular behaviour.  
In summary, apoptosis is regulated by an extremely complex machinery of pro- and 
antiapoptotic signals, which are balanced in a healthy cell and shifted out of this equilibrium 
in cancer cells.  
 
Limitless replicative potential 
In addition to signals regulating the growth properties of a cell in response to its 
environment, the life span of a normal cell underlies an intrinsic program limiting its 
replicative potential. Non-transformed cells in culture have the capacity to divide only about 
60-70 times. With increasing cell divisions they undergo a process termed senescence and 
stop growing. This process can be circumvented for example by blockage of the pRb and the 
p53 tumour suppressor genes, enabling the cell to further multiply until a second state called 
crisis, is reached.  This state is characterized by massive cell death and increased karyotypic 
rearrangements, like chromosome fusions, and eventually enables a cell to replicate without 
limit (Wright et al., 1989). Most isolated tumour cells demonstrate this immortalization in 
culture, arguing for immortalization as a prerequisite for cancer to evolve. However, 
theoretically 60-70 doublings are more than enough for a cell to expand to a life-threatening 
tumour mass. On the other hand, the apoptotic rate within tumours is high and the actual cell 
number of a tumour greatly under represents the cell generations required to produce it. As a 
result of this, limitless replicative potential would be a prerequisite for cancerous 
transformation.  
The molecular mechanism underlying senescence is based on the replication of the 
genomic material. During each cell cycle the whole genome is replicated but the ends of the 
chromosomes, called telomers are shortened through each round of replication, due to the 
inability of the appropriate polymerase to replicate the chromosome completely. Telomers do 
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not carry any genomic information, but protect the ends of the chromosomal DNA. They 
prevent end to end fusions and karyotypic misarrangements, which are associated with crisis 
and result in the death of the cell (Counter et al., 1992). Telomer stability is observed in 
nearly all types of cancer and cancer cells maintain the integrity of their telomers by over-
expressing an enzyme called telomerase, which elongates the telomeric DNA and 
compensates for the shortening during replication (Bryan and Cech, 1999). To a lesser extent, 
telomer maintenance in cancer cells can also be achieved by recombination-based 
interchromosomal exchanges of sequences termed ‘alternative lengthening of telomers’ 
(ALT) (Bryan et al., 1995).  
 
Sustained angiogenesis 
Every growing tissue is dependent on supply with nutrition and oxygen, which is 
guaranteed in healthy tissue by a dense network of blood vessels. Tumours also depend on 
the vasculature to be able to grow beyond a certain size. During tissue development the 
formation of blood vessels from pre-existing vessels (angiogenesis) and the de novo 
formation of new blood vessels (neovascularization) is regulated by complex interactions 
between the tissue and the endothelial cells of the vasculature. Positive and negative 
regulators of angiogenesis are tightly balanced and transiently regulated in order to induce 
blood vessel outgrowth. Mainly soluble factors, like ‘vascular endothelial growth factors’ 
(VEGFs) and ‘fibroblast growth factors’ (FGFs), which attract endothelial cells expressing 
the cognate surface receptors (Veikkola and Alitalo, 1999) or inhibitors of angiogenesis like 
thrombospondin (Bull et al., 1994) regulate the process of neovascularization. In order to 
grow out into a macroscopic tumour, cancer cells have to interfere with this programme by 
shifting the balance to the angiogenic inducers and counteracting the inhibitors (Hanahan and 
Folkman, 1996). Indeed many tumours reveal enhanced expression of VEGFs and FGFs and 
impaired expression of thrombospondin (Singh et al., 1995; Volpert et al., 1997). Activators 
or inhibitors of angiogenesis can also be stored in the ECM and released by proteases, that 
are expressed by tumour cells (Whitelock et al., 1996). The importance of sustained 
angiogenesis for tumour growth has been shown in several studies (Bouck et al., 1996; 
Hanahan and Folkman, 1996; Folkman, 1997) and is a target for therapeutic intervention.  
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Tissue invasion and metastasis 
90% of human cancer deaths are due to the formation of secondary tumours (Sporn, 
1996) arising from cells, that moved out of the primary tumour mass and settled at distant 
sites in the body. The metastatic spread of tumour cells can be understood as a multistep 
process itself. In order to settle at a secondary site and to form a new tumour, a cancer cell 
has to acquire the ability to break down cell-cell and cell-matrix connections, invade adjacent 
tissues by overcoming tissue borders and acquire a migratory phenotype. Then, metastatic 
cells have to enter the blood circulation or the lymphatic system to be transported to distant 
sites, where they have to exit the circulation again in order to form secondary tumours 
(Fig.2).  
 
Fig. 2: Two routes of metastasis formation 
Tumour cells disseminate from the primary tumour and invade adjacent tissues. After intravasation 
they use the blood or the lymphatic system for transportation. Via lymphatic dissemination the cells 
are transported to lymph nodes, where metastases are formed. Subsequently, tumour cells can enter 
the blood system through this route as well. Circulating tumour cells in the blood have to attach to the 
endothelial vessel wall, extravasate and settle at a secondary site to form distant metastases. Adapted 
by permission from Macmillan Publishers Ltd: Nature Reviews Cancer (Pantel and Brakenhoff, 
2004).  
 
 
The first step during the metastatic process is the dissemination from the primary 
tumour mass. Adhesion to neighbouring cells and to the ECM is lowered by metastasising 
cells through modulating the functions of cell adhesion molecules (CAMs) of the 
immunoglobulin, cadherin and integrin families and other CAMs. For example, the function 
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of E-cadherin, a homotypic cell-cell interaction molecule ubiquitously expressed on all 
epithelial cells, is altered in many carcinomas during progression towards malignancy 
(Christofori and Semb, 1999). The loss of E-cadherin mediated cell-cell adhesion has been 
proposed to be a prerequisite for tumour cell invasion and metastasis (Birchmeier and 
Behrens, 1994). Indeed re-establishing functional E-cadherin expression could reverse the 
invasive phenotype of cultured tumour cells (Vleminckx et al., 1991; Birchmeier and 
Behrens, 1994). The loss of E-cadherin expression often is accompanied by de novo 
expression of motility promoting cadherins, like N-cadherin (Li and Herlyn, 2000; Tomita et 
al., 2000). Such a ‘cadherin switch’ occurs during normal embryonic development, when 
epithelial cells acquire a migratory phenotype (Hatta and Takeichi, 1986; Bendel-Stenzel et 
al., 2000). Another prominent example is N-CAM, the expression of which is switched from 
a highly to a poorly adhesive isoform in certain cancers (Johnson, 1991; Kaiser et al., 1996) 
or is generally downregulated in others (Fogar et al., 1997). Finally, cancer cells are able to 
adapt to a new environment and to modulate their interaction with matrix components, such 
as collagen, laminin etc., e.g. by changing their integrin repertoire. It has been reported that 
tumour cells can switch integrins in a way that attachment to proteolytically degraded ECM 
components and migration is favoured over tight adhesion to normal epithelial matrix. 
(Varner and Cheresh, 1996; Lukashev and Werb, 1998).  
In order to invade adjacent tissues, tumour cells may express extracellular proteases 
by themselves or induce their expression in neighbouring stromal cells (Werb, 1997). 
Degradation of matrix components by proteases enables tumour cells to overcome restrictions 
due to cell-cell contacts and to invade neighbouring tissues. Prominent examples are the 
‘matrix metalloproteases’ (MMPs), a family of secreted or transmembrane proteases capable 
of degrading various matrix components. Cancer cells can also deregulate MMP function by 
modulating the expression of specific inhibitors (TIMPs) or of molecules that activate MMPs 
through enzymatic cleavage.  
Cancer cells use the blood circulation or the lymphatic system for transportation to 
secondary sites. To enter a blood vessel a cancer cell has to pass the endothelial cell layer, a 
process called intravasation. The majority of cells entering the blood stream will die due to 
mechanical stress or elimination by the immune system, a process called immune 
surveillance (Jakobisiak et al., 2003). Because lymphatic vessels consist of more loosely 
associated cells the lymphatic system is easier to enter (Alitalo and Carmeliet, 2002). 
Although vascular and lymphatic spread of tumour cells share the basic features, the 
molecular mechanisms might differ. Once transported to a secondary site, a cancer cell has to 
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rest and extravasate out of the circulation, which means that the cell has to build up adhesive 
properties again to be able to settle. In order to grow out and form a new tumour mass a 
cancer cell has to adapt to the new environment, build up cell-cell and cell-matrix contacts 
again and fulfil all the described capabilities to form a massive tumour.  
In conclusion, the process of metastatic outgrowth above all requires dynamic 
adhesive properties of cancer cells, switching between a sessile and a motile state when 
needed. Recent evidence highlights that the crosstalk of a cancer cell and the 
microenvironment at both the primary and the secondary site plays a key role for the 
metastatic success of cancer cells (reviewed by Schedin and Elias, 2004).  
 
 
1.2  The BSp73 cell system 
 
In order to study late steps in tumour progression cell systems have been established, 
comprising two related cell lines, which exhibit differences in their metastatic potential. 
These cell lines may originate from the primary tumour and a metastatic lesion or may 
present two subclones derived from the same primary tumour. The BSp73 tumour cell system 
represents such a model. A stable cell line BSp73 was established from a spontaneous 
pancreatic adenocarcinoma of a BDX rat (Zoller et al., 1978). Several in vivo passages after 
subcutaneous application gave rise to tumours with different metastatic potential and finally 
led to the establishment of two subclones of BSp73. One clone, BSp73AS (AS), displaying 
only weak metastatic growth, whereas the other, BSp73ASML (ASML), exhibits a very high 
metastatic potential (Matzku et al., 1983). When injected into the footpad of syngenic rats, 
AS cells show strong local tumour growth but only reach the draining lymph nodes. In 
contrast, ASML cells display only very limited local tumour growth, rapidly spread through 
the lymphatic system and form miliary metastases in the lung, which will finally kill the 
animal. Different to AS cells which show a spread out epithelial morphology with long 
filopodia, ASML cells display a rounded cell shape without any visible spreading on 
substrate and a very limited ability to bind to matrix components, such as laminin, fibronectin 
and collagen. Moreover, these cells do not form a closed monolayer but rather detach from 
the substrate before reaching full confluency. (Matzku et al., 1985; Ben-Ze’ev et al., 1986; 
Raz et al., 1986).  
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Generation of monoclonal antibodies against membrane preparations of the two cell 
lines (Matzku et al., 1989) led to the identification of 5 differentially expressed surface 
molecules, namely a variant isoform of the cell adhesion molecule CD44 (Gunthert et al., 
1991), the α6β4 integrin (Herlevsen et al., 2003), C4.4A, a molecule showing high homology 
to the uPA receptor (Rosel et al., 1998), the ephithelial cell adhesion molecule EpCAM 
(Wuerfel et al., 1999) and the tetraspanin D6.1A (Claas et al., 1998). Subsequent expression 
profiling of two sublines revealed several hundred differentially expressed genes (Nestl et a., 
2001; Tarbe et al., 2002).  
 
 
1.3  The cell-cell and cell-matrix adhesion molecule CD44  
 
One of the first molecules being described to be involved in metastasis formation is 
CD44. The described BSp73 cell system was used to show that a single CD44 splice variant 
conferred metastatic potential to the otherwise locally growing BSp73AS tumour (Gunthert et 
al., 1991). CD44, first assigned as ‘lymphocyte homing receptor’ (Gallatin et al., 1983), is a 
broadly distributed single pass transmembrane glycoprotein involved in several physiological 
and pathological processes including development, wound healing, inflammation, 
haematopoiesis, immune response and tumour progression (Herrlich et al., 1998; Naor et al., 
1997; Ponta et al, 2003). Posttranslational modification and excessive alternative splicing 
give rise to a diverse pool of proteins ranging between 80 and 200 kDa in size. 
 
1.3.1  Structural properties of CD44 
 
The CD44 gene locus spans about 50 kb of genomic DNA and is highly conserved 
among vertebrates (Naor et al., 1997). The corresponding pre mRNA consists of 20 exons, 12 
of which can be regulated by alternative splicing (Gunthert et al., 1991; Screaton et al., 1992; 
Tolg et al., 1993; reviewed by Naor et al., 1997; Lesley et al., 1998). Theoretically, about 
1000 putative different splice products can be generated in this way, but apparently not all 
combinations are expressed (Naor et al., 1997). The shortest CD44 isoform, called standard 
isoform (CD44s), with all variant exons excised, is expressed in nearly all vertebrate cells 
(Naor et al., 1997), while variant isoforms, named after the variant exons contained, show a 
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highly restricted expression pattern during embryonic development, in pathological 
backgrounds or in a cell type specific manner. Alternative splicing can be dynamically 
regulated depending on the activation state of the cell (Arch et al., 1992). Examples for cell 
type specific variants are CD44v8-v10, which is present on epithelial cells, while CD44v3-
v10 is expressed by keratinocytes (Fig. 3).   
 
Fig. 3: Exon map of CD44 and examples for variant isoforms  
A.  Exon map of CD44 B. Examples for variant isoforms, named by the variant exons they contain. 
EC extracellular domain, TM transmembrane domain, CP cytoplasmic domain.  
 
 
The CD44 protein consists of a large extracellular domain, made up of the amino-
terminal part and a short membrane proximal stem structure, the transmembrane region and a 
cytoplasmic tail. Up to ten variant exon products can be inserted in the stem structure. In 
addition to this, a short version carrying a short cytoplasmic tail exists, which is only very 
rarely expressed (Goldstein and Butcher, 1990) (Fig. 4).  
The extracellular domain of CD44 can be modified by N- and O-linked glycosylation 
and contains binding sites for hyaluronic acid (HA) and other glycosaminoglycans (GAGs) 
(Naor et al., 1997). Insertion of variant exons can lead to additional modifications. For 
example, variant exon 3 (v3) carries a site for heparan sulfate (HS) or chondroitin sulfate 
(CS) modifications (Bennett et al., 1995). Through its GAG binding sites CD44 can bind to 
GAG modified proteolycans such as versican (Kawashima et al., 2000), aggrecan (Fujimoto 
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et al., 2001) and serglycin (Toyama-Sorimachi et al., 1995). However, the functional 
relevance of this property is unclear. The extracellular domain of CD44 can be shed from the 
surface by proteolytic cleavage within the stem structure (Okamoto et al., 1999).  
 
Fig. 4: Structure of the CD44 molecule 
CD44 is a single pass transmembrane protein. The large extracellular domain carries binding sites for 
glycosaminoglycans, such as hyaluronic acid and sites for posttranslational modifications. 10 variable 
exons can be inserted into the stalk domain by alternative splicing. The short cytoplasmic tail can be 
linked to the cytoskeleton via ERM proteins and Ankyrin.  
  
 
The transmembrane domain, encoded by exon 18 is supposed to be involved in CD44 
oligomerization and localization in raft like membrane microdomains (Liu and Sy, 1997; 
Neame et al., 1995; Perschl et al., 1995), which are known to serve as signalling platforms. 
The cytoplasmic domain was shown to interact with a multitude of molecules and is 
important for linking CD44 to the cytoskeleton. The cytoplasmic tail of CD44 can be 
phosphorylated by protein kinase C (PKC), which influences its ability to interact with other 
proteins, as shown for ezrin (Legg et al., 2002). Upon shedding of the extracellular domain, 
the cytoplasmic part is cleaved and translocates to the nucleus where an effect on 
transcriptional regulation was demonstrated (Okamoto et al., 2001; reviewed by Nagano et 
al., 2004).   
 
         
Introduction 
 16 
1.3.2  Different modes of interactions for CD44 
 
A multitude of functions has been attributed to CD44 and its variants in different 
functional contexts, such as morphogenesis and organogenesis (reviewed by Knudson and 
Knudson, 1993), haematopoiesis (Ghaffari et al., 1999) and various immune functions, 
including homing and migration of lymphocytes and leukocyte activation and effector 
functions (reviewed in Naor et al., 1997; Pure and Cuff, 2001). The diversity of cellular 
processes influenced by CD44, e.g. growth regulation, survival, differentiation, adhesion and 
motility, raises the question how this can be achieved by a single molecule. Of course, one 
reason lies in the heterogeneity of the CD44 protein family with different variants each 
having unique characteristics. A second explanation might be the ability of CD44 to function 
in different ways. First as a ligand binding surface receptor, mainly by interacting with its 
principle ligand hyaluronic acid, second as a co-receptor for other surface molecules, 
modulating for example the signalling of associated growth factor receptors, and third 
through interactions with cytoplasmic molecules and as organizer of the actin cytoskeleton.  
 
CD44 as a cell surface receptor 
CD44 functions as the main hyaluronic acid receptor (Culty et al., 1990) but binding 
was also demonstrated for other components of the ECM, namely fibronectin, laminins and 
collagens (Turley and Moore, 1984) and also for cytokines like osteopontin and RANTES 
(Weber et al., 1996; Wolff et al., 1999). The corresponding binding site for HA is located in 
the standard part of the protein, but the affinity might be influenced by insertion of variant 
exons (Sleeman et al., 1996b) or by the state of glycosylation (Skelton et al., 1998). 
Moreover, binding to HA is not a constitutive ability of CD44 expressing cells but can be 
regulated from within the cell.  
Hyaluronic acid belongs to the family of glycosaminoglycans, but different from all 
other GAGs, HA does not possess a protein component. Instead it displays a simple structure 
as a large polysaccharide, exclusively composed of repeating disaccharides of glucoronic 
acid and N-acetylglucosamine. Under physiological conditions HA consists of 2000 to 2500 
disaccharides, corresponding to a molecular mass of 106-107 Da and a polymer length of 2-
25µm. HA is a major component of the extracellular  and pericellular matrix (Lee and Spicer, 
2000) and due to its hygroscopic characteristic it plays an important role in tissue 
homeostasis and biomechanical integrity. The role of CD44 in many physiological and 
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pathological processes is based on its interaction with HA. By binding to its ligand, CD44 
can mediate adhesion to and migration on HA rich matrices and these processes can be 
regulated by modulation of the binding affinity or by enzymatic cleavage of the extracellular 
portion of CD44 (Okamoto et al., 1999-2). Moreover, CD44 expression can influence the 
synthesis and endocytosis of HA (Culty et al., 1992; Hua et al., 1993).  
CD44 was shown to recruit and regulate the activity of proteases on the cell surface. 
For example, MMP9 (Bourguignon et al., 1998) and MMP7 (Yu et al., 2002) were 
demonstrated to associate with CD44 and their function was dependent on this co-
localization. In addition, growth factors and cytokines are captured by CD44, which can be 
variant specific as it is discussed for osteopontin (Katagiri et al., 1999). Growth factors 
described to bind to CD44 are ‘hepatocyte growth factor’/‘scatter factor’ (HGF/SF), ‘basic 
fibroblast growth factor’ (bFGF) and ‘heparin-binding factor’ (Sherman et al., 1998; van der 
Voort et al., 1999; Jones et al., 2000). The enrichment of soluble molecules on the surface by 
CD44 can influence outside in signalling either directly via binding to CD44 or indirectly by 
regulating the binding to other receptors.  
 
CD44 as a ‘co-receptor’ for other transmembrane proteins 
Lacking a catalytic domain itself, CD44 can act as a co-receptor for protein tyrosine 
kinases (PTKs) like growth factor receptors. For example, CD44v6 has been demonstrated in 
several cell lines to be essential for proper binding of HGF to its cognate receptor c-
Met/HGF-R through complex formation (Orian-Rousseau et al., 2002). A second prominent 
example is the ErbB family of receptor tyrosine kinases, with some members showing 
dependence on complex formation with CD44 for proper activation (Bourguignon et al., 
1997; Sherman et al., 2000). The nature of this co-receptor function might be due to 
clustering of receptor subunits and stabilisation of receptor dimers or, as in the case of ErbB4, 
by supporting activation of the ligand via proteolytic cleavage through associated MMPs as 
mentioned above (Yu et al., 2002). Given the heterogeneity of the CD44 protein family, 
functioning as a co-receptor could explain the ability of CD44 to modulate several different 
signalling circuits, without any direct signal transfer through CD44 itself ever being 
demonstrated. CD44 also associates with other transmembrane proteins without catalytic 
activity, for instance tetraspanins and other adhesion molecules such as integrins or EpCAM 
(Schmidt et al., 2004; Ladwein et al., 2005).  
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CD44 as an associating molecule with cytoplasmic proteins and as organizer of the actin 
cytoskeleton 
Several intracellular molecules were shown to associate with the cytoplasmic tail of 
CD44. Importantly, CD44 can be crosslinked to the actin cytoskeleton via binding to ankyrin 
and members of the ERM proteins (for ezrin, radixin and moesin) (Tsukita et al., 1994; 
Bourguignon and Jin 1995). ERM proteins are involved in the regulation of cell shape, cell 
migration and protein resorting in the plasma membrane (Bretscher et al., 2002; Gautreau et 
al., 2002) and CD44 was demonstrated to influence these processes through interaction with 
ERM proteins. Even though, the precise mechanism, e.g. if this leads to actin contraction, 
polymerization or depolymerization is not clear. The binding affinity for ERM proteins is 
tightly regulated and seems to be higher for variant CD44 than for the standard isoform 
(Tsukita et al, 1994). Other associated molecules include cytoplasmic kinases like Src, PKC, 
LCK and Fyn and the guanine nucleotide exchange factors TIAM1 and VAV2 (reviewed by 
Naor et al., 1997; Bourguignon et al., 2000; Bourguignon et al., 2001a+b). 
 
 
1.3.3  Physiological and pathological functions ascribed to CD44 
 
As mentioned above, the physiological roles of CD44 are surprisingly diverse. The 
fact that CD44 knock-out (k.o.) mice are viable and show only a very mild phenotype with 
regard to haematopoiesis as well as lymphocyte activation and migration (Schmits et al., 
1997; Protin et al., 1999) argues for other molecules being able to compensate for the loss of 
CD44 during embryonic development. However, antibody blockade led to a retardation of 
development (Zoller et al., 1997). This corresponds to the observation that the k.o. phenotype 
became more obvious, when CD44-/- animals were challenged, for example by infection with 
pathogens or by artificial induction of autoimmune diseases and proved a role for CD44 in 
the immune system. The same holds true in variant specific k.o. mice (Wittig et al., 2000).  
 
CD44 in development 
Expression of CD44 during embryonic development has been investigated in several 
studies. However a defined role for CD44 was demonstrated only in a few cases, for example 
in axon guidance during the formation of the optic chiasm (Stretavan et al., 1994, 1995), 
during limb bud development (Sherman et al., 1998), and in uteric bud and mammary gland 
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development (Pohl et al., 2000). Expression of variant CD44 during embryogenesis is seen 
on most epithelial and haematopoietic cells (Wirth et al., 1993; Terpe et al, 1994; Weber et 
al., 1996), while the expression in adult animals is mainly restricted to the skin, the 
epithelium of the gut, some glands and subpopulations of the haematopoietic cells (Kennel et 
al., 1993; Wirth et al., 1993; Fox et al., 1994; Hirano et al., 1994). Several studies 
demonstrated an important function of CD44 for differentiation and proliferation of 
haematopoietic progenitor cells (Ghaffari et al., 1999).  
 
CD44 in inflammation and leukocyte extravasation  
Physiological functions of CD44 are best explored in haematopoietic cells and 
important roles for CD44 and HA were shown in inflammatory processes (Pure et al., 2001). 
The physiological importance of CD44 in this context was shown for example in autoimmune 
diseases like rheumatoid arthritis and many others (Brennan et al., 1997; Seiter et al., 1999; 
Stoop et al., 2001). During inflammation, leukocytes exit the circulation to enter into 
different tissues. The first step of this process, a loose attachment of the leukocytes to the 
vessel wall, termed ‘rolling’, is mediated by selectins on leukocytes binding to carbohydrate 
ligands on the endothelium. This primary interaction is followed by a secondary ‘firm 
adhesion’, mediated by integrins and subsequent extravasation (Albelda et al., 1994). There is 
increasing evidence that CD44 contributes to both, rolling and firm adhesion. CD44 on the 
surface of leukocytes was shown to mediate rolling on the vessel wall via interaction with 
endothelial HA (De Grendele et al., 1996/1997).  
 
CD44 in pericellular matrix assembly 
HA is a key player in the assembly of pericellular matrices through interactions with 
proteoglycans and other extracellular macromolecules. CD44 was shown to be the main HA 
anchoring molecule for these processes in chondrocytes, the main cartilage cell type 
(Knudson et al. 1996). Thereby, the presence of CD44 has implications for organizing the 
structure of the cartilage. Other cell types like fibroblasts are also able to form such a 
pericellular matrix (Hedman et al., 1979), which may be important for their locomotion 
(Turley et al., 1989). Although tumour cells usually do not synthesize their own pericellular 
matrix, they often have the ability to assemble one in the presence of exogenously added HA 
and aggregating proteoglycans (Knudson and Knudson, 1991). 
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1.3.4  CD44 in tumour progression 
 
A role of CD44 for tumour progression is well documented (reviewed by Ponta et al., 
1998; Naor et al., 2002; Marhaba and Zoller, 2004). The observation that variant CD44 is 
overexpressed in several metastatic tumours (Matsumura et al., 1992) raised the question 
whether CD44 might be predictive for metastasis formation. Several studies tried to define 
CD44 as prognostic marker, but correlations vary between different kinds of cancer, states of 
disease and the CD44 isoform being examined (Wielenga et al., 1993; Pals et al., 1997; Dall 
et al., 1994). However numerous studies have demonstrated that CD44s and especially 
variant CD44 is implicated in different aspects of tumour progression and particularly in 
metastatic spread. A direct evidence for this was demonstrated in a CD44 k.o. mouse model, 
showing unaltered primary tumour growth but inhibited sarcoma metastasis formation 
(Weber et al., 2002). Recently, CD44 could be identified as a key regulator for leukemic stem 
cell fate by blocking homing to the bone marrow (Jin et al., 2006). However, it has to be 
mentioned, that in prostate cancer cells overexpression of CD44s suppressed their metastatic 
capacity (Gao et al., 1998).  
Deregulation of variant CD44 in several cancers is not surprising, taken into account, 
that aberrant alternative splicing is frequently seen in cancer cells (reviewed by Kalnina et al., 
2005) and CD44 being most profoundly subjected to alternative splicing. This and the 
remarkable functional diversity of CD44 provide an explanation as to how one molecule can 
fulfil several different tasks of tumour progression. In fact, CD44 is described to influence 
most of the proposed acquired capabilities needed for successful tumour progression.  
The interaction between CD44 and HA has been described to trigger proliferation of 
several tumour cell lines, such as melanoma cells (Ahrens et al., 2001), mammary carcinoma 
(Peterson et al., 2000), glioma (Akiyama et al., 2001) and malignant mesothelioma cells 
(Nasreen et al., 2002). On a molecular level CD44 was also demonstrated to promote tumour 
cell proliferation through its co-receptor function as mentioned above, by activating members 
of the ErbB receptor family (Bourguignon et al, 2001, Ghatak et al., 2005) and c-Met (Orian-
Rousseau et al., 2002, Recio et al., 2003). In addition CD44v6 is able to directly induce 
proliferation by activating the MAP kinase pathway (Marhaba et al., 2005). In contrast, CD44 
was also found to act as a tumour suppressor. Binding of CD44 to HA has been reported to 
inhibit cell growth during contact inhibition (Morrison et al., 2001) and induce terminal 
differentiation of myeloid leukemia cell lines (Charrad et al., 2002).  
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The influence of CD44 on apoptosis is even more controversial than on proliferation. 
In lymphoma and thymocytes CD44 engagement was shown to induce apoptosis through up-
regulation of the proapoptotic molecule Bax and down-regulation of the antiapoptotic 
molecule Bcl-XL (Guy et al., 2002). Proapoptotic effects of CD44 were also shown for 
dendritic cells and neutrophils (Yang et al., 2002; Takazoe et al., 2000). On the other hand, 
there are several examples for CD44 induced survival by suppressing the induction of 
apoptosis (Bates et al., 1998; Allouche et al., 2000). Survival-promoting functions of CD44 
can be mediated by the PI3K-Akt pathway (Bates et al., 2001; Ghatak et al., 2002), or 
through upregulation of antiapoptotic molecules like Bcl-2 and Bcl-XL (Khan et al., 2002; 
Marhaba et al., 2003). Moreover CD44 can also downregulate Fas expression, thereby 
inhibiting apoptosis in lung cancer cells (Yasuda et al., 2001), or inhibit Fas signalling 
through interaction with the receptor (Mielgo et al., 2006). Notably, these prosurvival effects 
are often attributed to variant CD44, like CD44v6 in colon carcinoma cells (Bates et al., 
1998) or CD44v7 in lymphocytes (Wittig et al., 2000; Marhaba et al., 2003).  
Factors known to stimulate vascularization are ‘basic fibroblast growth factor’ 
(bFGF), ‘vascular endothelial growth factor’ (VEGF) and cytokines such as ‘transforming 
growth factor β (TGFβ) (Pepper, 1997). MMP2 and MMP9 associated with CD44 were 
demonstrated to cleave the pro-form of TGFβ, thereby releasing the active cytokine and 
inducing angiogenesis (Yu and Stamenkovic, 1999, 2000). Other described angiogenic 
effects of CD44 are mainly due to its expression on endothelial cells rather than on tumour 
cells (Griffioen et al., 1997).  
Finally, CD44 might influence the formation of metastatic lesions in several different 
ways. CD44-HA binding can influence the adhesive properties of tumour cells to the ECM. 
Modulation of this interaction can enhance the mobility of cancer cells during the metastatic 
process. For example HA-CD44 binding was shown to be important for glioma cell invasion 
and migration (Okada et al., 1996). Additionally, the loss of ECM contacts by cleavage of 
CD44 has been demonstrated (Okamoto et al., 1999). The loss of cell-matrix adhesion 
usually leads to growth arrest and cell death and CD44 was shown to be able to promote 
anchorage-independent growth, a prerequisite for invasion (Peterson et al., 2000; Ghatak et 
al., 2002).  
The activation of cell surface MMPs by CD44 favours invasiveness of tumour cells, 
enabling them to migrate into adjacent tissues as demonstrated for MMP9 (Yu and 
Stamenkovic 1999, 2000). Migration of cells requires reorganization of the actin 
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cytoskeleton, which is under the control of Rho GTPases, like RhoA, Rac1 and Cdc42. HA 
binding to CD44 can activate Rac1 and induce lamellipodia formation and migration 
enabling invasive behaviour (Oliferenko et al., 2000; Bourguignon et al., 2000).  
As already described in the context of inflammation, CD44v was shown to facilitate 
attachment of lymphoma cells to vessel walls through interaction with endothelial surface 
HA (Wallach-Dayan et al., 2001), facilitating subsequent firm adhesion and transmigration 
into the underlying tissue and favouring settlement of tumour cells at a secondary site. 
Indeed, a soluble form of CD44 competing with cell surface CD44 for HA binding reduced 
metastasis formation in vivo (Yu et al., 1997; Peterson et al., 2000).  
In summary, published data clearly show that CD44 and especially variant CD44 play 
a crucial role in the course of tumour progression and metastasis formation. 
 
 
1.4  RNA interference as a tool to study isoform specific gene 
 functions 
 
RNA interference (RNAi) depicts an evolutionary conserved mechanism, occurring in 
most eukaryotic organisms (Hannon, 2002), which may have evolved as defense system 
against viral and genetic parasites. Double stranded (ds) RNA molecules are processed into 
short RNA duplexes, directing sequence specific cleavage or translational repression of 
complementary messenger RNAs (reviewed by Meister and Tuschl, 2004) and are implicated 
in chromatin remodeling and transcriptional regulation (reviewed by Lippman and 
Martienssen, 2004). In addition to the growing importance of RNAi as a tool for 
manipulating gene expression, the endogenous triggers of the RNAi pathway, called 
microRNAs (miRNAs) recently attracted great interest and were shown to play a role during 
embryonic development and to be implicated in tumourigenesis as well (reviewed by 
O’Rourke et al., 2006; Esquela-Kerscher and Slack, 2006).  
 Upon the original observation that ds RNA triggers are far more efficient in gene 
silencing than single stranded (ss) antisense RNA molecules (Fire et al., 1998), RNAi became 
a popular tool for modulating gene expression in model systems like C.elegans and 
Drosophila. However the subsequent adaptation of the RNAi technique to the mammalian 
system (Elbashir et al., 2001) made RNAi one of the most profound discoveries of the last 
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decade and one of the most powerful techniques for studying gene function in a cell culture 
based system and probably even as therapeutic tool in vivo. Compared to other techniques, 
such as antisense technology or morpholino oligos, only RNAi enables splice variant specific 
down regulation of gene products even on a stable basis. Isoform specificity can be achieved 
by choosing exon specific target sequences and stable downregulation of the gene of interest 
can be realized through integration of expression cassettes, driving transcription of self 
complementary short hairpinRNAs (shRNAs), that are processed by the endogenous RNAi 
machinery into active small interfering RNAs (siRNAs) (Paddison et al., 2002; 
Brummelkamp et al., 2002). Thus, RNAi allows stable and isoform-specific loss-of-function 
studies, which were rarely practical by conventional k.o., due to the hyperploidity of many 
tumour cells. 
 
1.5  Aims of the thesis 
 
 The aim of this work was to investigate the contribution of CD44v on the metastatic 
behaviour of ASML cells and to gain a better understanding of the role of variant CD44 
during the lymphatic spread of tumour cells in general.  
 Due to its remarkable structural and functional heterogeneity, CD44 plays a pivotal 
role in several steps of tumour progression. First evidence for the importance of CD44 
variants in metastasis formation was obtained in the rat pancreatic adenocarcinoma model 
BSp73, where two major splice variants expressed only by the highly metastatic ASML 
subline were identified as v4-v7 and v6/v7. Introduction of these isoforms conferred a 
metastatic phenotype to the otherwise only locally growing AS subline, exclusively 
expressing the standard CD44 isoform (Gunthert et al., 1991; Rudy et al., 1993). Moreover, 
application of antibodies targeting variant exon 6 retarded metastasis formation of ASML 
cells, providing a hint, that CD44v also plays a crucial role in the metastatic spread of these 
cells (Seiter et al., 1993). On the other hand, compared to ASML cells, AS cells display 
entirely different adhesion and migration characteristics. In addition to this, expression 
profiling revealed several hundred differentially expressed genes between these two sublines 
(Tarbe et al., 2002), including molecules known to play a role in cancer progression, such as 
c-Met and c-Myc.  
In order to investigate specific functions of CD44v and the underlying molecular 
mechanisms in metastasis formation, a plasmid based RNAi system was used for creating 
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stable and variant specific CD44 knock-down cells of the highly metastatic carcinoma cell 
line BSp73ASML. The resulting phenotype was studied in vitro and in vivo, particularly 
emphasising interactions of CD44v with the microenvironment and the stimuli the tumour 
cell may receive by this crosstalk.  
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2.  Results 
 
A plasmid-based RNAi system (pSuper) was used to create stable and variant 
specific knock-down cells of the highly metastatic tumour cell line BSp73ASML 
(ASML), known to express CD44 variants at high levels. The plasmid drives expression 
of small hairpin RNAs, which are processed into functional siRNAs and eventually lead 
to sequence-specific down-regulation of the gene of interest. In addition, it carries a 
GFP reporter and a neomycin resistance for detection of transfected cells and selection 
of stable clones (Fig. 5). Constructs were designed on the premise to target the two 
most abundant CD44 variants expressed by ASML, namely CD44v4-v7 (meta1 isoform) 
and CD44v6/v7 (meta2 isoform), previously described to confer metastatic potential to 
the otherwise weakly metastatic sister subline BSp73AS (Rudy et al., 1993). Target 
sequences therefore lie within the variant exons contained in both isoforms. Construct 
‘v6’ targets variant exon 6, ‘v7’ targets variant exon 7 and ‘v6/v7’ targets the border of 
exon v6 and v7. Constructs were cloned and verified by sequencing.  
 
Fig. 5: Expression cassettes of ‘pSuperGFPneo’ carrying construct ‘v7’ 
The self-complementary sequence of the transcript folds into a hairpin structure, which is processed 
by the endogenous RNAi machinery into an active siRNA. A GFP-reporter and a neomycin resistance 
are included in a second expression cassette.  
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2.1  Establishment of stable CD44vk.d. cell lines and rescue clones 
2.1.1  RNAi construct evaluation by FACS and fluorescence microscopy  
 
Efficiency in down-regulation of variant CD44 was monitored by FACS staining after 
transient transfection of ASML cells with three different pSuper-constructs and the empty 
vector (mock). Three days after transfection, cells were analyzed for CD44v expression by 
FACS staining using an antibody specific to variant exon 6 (A2.6). The mean intensity of 
GFP positive (transfected) cells was compared to GFP negative cells of the same pool and 
revealed functionality of the ‘v7’ and the ‘v6/v7’ constructs in down-regulating CD44variant 
expression on ASML cells. Table 1 shows the relative mean values of three experiments. 
While ‘mock’ transfection did not change CD44v expression and pSuper-v6 showed only 
weak down-regulation, transfection with pSuper-v7 reduced the mean intensity of CD44v by 
55% and transfection with pSuper-v6/v7 resulted in a mean intensity reduced by 51%.  
 
Tab. 1: Evaluation of pSuper constructs by FACS staining 
construct relative mean intensity for CD44v 
pSuper-mock 108 ± 6% 
pSuper-v6 86 ± 5% 
pSuper-v7 45 ± 4% 
pSuper-v6/7 49 ± 6% 
FACS staining for CD44v6 (A2.6) after transient transfection with different pSuper constructs and the 
empty vector. Mean intensities of transfected (GFP positive) relative to untransfected cells are shown 
in percent.  
 
 
Results were confirmed by immunofluorescence microscopy. ASML cells grown on 
coverslips were transfected with the three pSuper constructs and the empty vector and stained 
after three days for variant CD44 expression. GFP positive cells in pSuper-v7 and pSuper-
v6/v7 transfections show reduced CD44 expression, while expression of other surface 
molecules like EpCAM is not affected (shown for pSuper-v7 in Fig. 6A). PSuper-v6 or mock 
transfected cells did not show a difference in CD44 expression (Fig. 6A, pSuper-v6 is not 
shown).  
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2.1.2  Establishment of stable CD44vk.d. clones by selection and recloning 
 
By selection with G418 and two rounds of recloning three stable clones of pSuper-v7 
transfected ASML cells were established that revealed strong down-regulation of variant 
CD44 on the protein level as shown by western blotting (Fig. 6B). CD44v levels are hardly 
detectable in the CD44v ‘knock-down’ (k.d.) clones, but unaffected in a stable ‘mock’ clone. 
EpCAM was used as an internal loading control. For unknown reasons no stable clones could 
be obtained with the pSuper-v6/7 construct.  
 
Fig. 6: CD44v expression of ASML cells is reduced after transfection with pSuper-v7 or 
the empty vector 
A. Immunofluorescence staining for CD44v6 with A2.6 (upper panels) or EpCAM with D5.7 (lower 
panel). GFP positive cells display reduced CD44v expression only in the pSuper-v7 transfections 
(middle panel), while mock transfection has no influence on the expression level (upper panel). 
EpCAM staining is not affected (lower panel). B. Western blot analysis of stable clones. Upper panel: 
the two major CD44 variants are down-regulated in the three knock-down clones, but unaffected in 
the mock clone. EpCAM is used as an internal loading control (lower panel).  
 
A      B 
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2.1.3  Restoring CD44 expression by introduction of mutated cDNAs 
 
In order to control specificity of any phenotype arising in the k.d cells, ‘rescue’ clones 
with restored expression of one of the dominant CD44 variants were established. This was 
achieved by introduction of cDNAs coding for either CD44v4-v7 or CD44v6/v7, carrying 
four silent point mutations in the v7 target sequence, which should protect them from 
degradation (Fig.7A). Indeed co-transfecting ‘HEK 293T’ cells with the ‘rescue’ cDNAs 
together with the pSuper-v7 construct showed high CD44 expression, while expression of a 
wt CD44 cDNA was significantly affected by pSuper-v7 co-transfection (data not shown). 
One of the k.d. clones, ASMLv71-14, was used for transfections with the ‘rescue’ cDNAs 
and after selection and two rounds of recloning stable ‘rescue’ clones were established. 
Western blot analysis for CD44variant expression shows successful restoration of either 
CD44v4-v7 or CD44v6/v7 in the knock-down clone, although CD44v4-v7 expression was 
not restored to levels comparable to the wt situation. One mock clone is shown as control.  
EpCAM serves as a loading control (Fig. 7B).  
 
Fig. 7: Restoring CD44 expression by transfection with mutated cDNAs 
Four silent mutations were introduced in the v7 target site of CD44v4-v7 and CD44v6/v7 cDNAs by 
PCR. The v71-14 clone was transfected with the mutated cDNAs and stable clones were established. 
A. v7 target and rescue sequence. Silent mutations are highlighted in red. B. Western blot analysis of 
stable clones, showing restored CD44v expression by A2.6 staining (upper panel). EpCAM is used as 
an internal loading control by D5.7 staining (lower panel).  
 
A  v7 target sequence AGAATGACAACACAGAGTCAAGAGGATG 
  v7 rescue sequence AGAATGACTACTCAGTCTCAAGAGGATG 
 
B 
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2.2  Characterization of the knock-down cell lines in vivo 
2.2.1  CD44vk.d. cells exhibit a reduced metastatic capacity in vivo 
 
Intra-footpad injections (ifp) of BDX rats with ASMLwt, one mock and three k.d. 
clones were performed and the metastatic spread was monitored. The metastatic growth of 
ASML cells has been studied before (Matzku et al., 1983) and displays only little local 
tumour growth, but rapid spread through the whole lymphatic system with massive tumour 
burden in the proximal lymph nodes and miliar outgrowth of micro metastases in the lung, 
which eventually lead to the death of the animal. Animals were injected ifp with 106 cells and 
sacrificed after 50 days. Diameters of the primary tumour and lymph node metastases were 
measured and lungs were photographed and weighed. In addition, lung samples were 
analyzed by immunohistological staining. ASMLwt cells as well as the mock clone 
resembled the expected metastatic behavior, but the CD44vk.d. clones showed clearly less 
metastatic growth. Two k.d. clones (v71-14 and v72-1-17) displayed a greatly reduced over 
all tumour burden in vivo, while one clone (v71-16) grew as fast as the wt and the mock 
controls in the lymph nodes, while the metastatic settlement in the lung was clearly 
diminished in all three clones, with most animals revealing tumour free lungs and some only 
few metastatic nodules. In comparison, the wt- and mock-injected animals all displayed 
entirely metastatic lungs.  
The metastatic burden of each lung was examined macroscopically (Fig. 8). The 
immense tumour burden in the lung of wt and mock treated animals is obvious by the size of 
the lungs that do not collapse, but are completely filled with tumour cells. Compared to this, 
the lungs of the CD44vk.d. clones appear normal or in the case of an v71-16-injected animal 
only moderately enlarged.  The weight of the lungs gives a good indication for tumour 
burden (Tab. 2). Two animals injected with ASMLwt died before the end of the experiment, 
obviously due to the tumour burden of the lung. In addition, immunohistochemical analyses 
of sectioned lung samples were performed. C4.4A was used as a tumour marker in this case 
and again demonstrates the immense tumour burden in the lungs of wt and mock injected 
rats, while lungs of the k.d.-treated animals were tumour free or exhibited only few nodules 
as shown for a v71-16 lung. In this case also the stability of the RNAi effect throughout the in 
vivo experiment is demonstrated, as the v71-16 lung was unstained for CD44v6, while wt and 
mock tumour tissue is strongly stained (Fig. 8).  
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Tab. 2: CD44k.d. clones exhibit a reduced metastatic growth in vivo 
In vivo metastasis assay #1. Ifp injections of BDX rats with ASMLwt, mock and CD44vk.d. clones. 
Animals were sacrificed and dissected after 50 days. The tumour burden is given as sum of primary 
tumour and lymph nodes. The mean for each group is shown. Lungs were macroscopically examined 
and the weight is given as an indication for tumour burden of the lung. Two ASMLwt animals marked 
with asterisks (*) died within the course of the experiment.  
 
The experiment was repeated with the rescue clones, displaying restored CD44v 
expression. One mock clone, one knock-down clone (v7 1-14) and one clone of each rescue 
construct were injected as before and animals were killed after 60 days and analyzed as 
described above. Again the mock-treated animals displayed massive tumour burden with 
miliary lungs, while the k.d. clone showed less metastasis formation without any tumour 
growth in the lungs. For unknown reasons the v4-v7 rescue clone did not grow in vivo, but 
four out of six animals injected with the CD44v6/v7 rescue clone displayed enhanced 
metastatic growth in the lymph nodes and five of six animals revealed also settlement in the 
lung, without reaching the massive tumour burden of the wt (Tab. 3). Immunohistology on 
tumour burden 
prim. tumour + lymph nodes  lung  
 
injected construct-
(animal#) tumour mass in 
cm3 
average morphology weight 
in g 
average 
untreated control-(1-1) - none 1.2 
untreated control-(1-2) - 
- 
none 1.3 
1.3±0.1 
ASMLwt-(1-1)* †day38 5.5 miliary, confluent 5.3 
ASMLwt-(1-2)* †day45 5.5 miliary, confluent 4.9 
ASMLwt-(2) 5.8 miliary, confluent 4.1 
ASMLwt-(3) 7.1 miliary, confluent 4.4 
ASMLwt-(4) 10.1 
6.9±2.1 
miliary, confluent 6.9 
5.1±1.1 
mock9-(5-1) 6.6 miliary, confluent 6.7 
mock9-(5-2) 3.7 miliary, confluent 2.4 
mock9-(6-1) 7.2 miliary, confluent 6.6 
mock9-(6-2) 8.0 miliary, confluent 5.5 
mock9-(7-1) 4.7 miliary, confluent 2.8 
mock-(7-2) 11.2 
6.9±2.6 
miliary, confluent 4.8 
4.8±1.8 
v71-14-(11) 2.7 none 1.2 
v71-14-(12-1) 3.2 none 1.1 
v71-14-(12-2) 3.5 none 1.3 
v71-14-(13-1) 4.2 none 1.3 
v71-14-(13-2) 5.0 none 1.9 
v71-14-(14-2) 2.1 
3.5±1.0 
none 0.9 
1.3±0.4 
v72-1-17-(15-1) 1.0 miliary, few 1.6 
v72-1-17-(15-2) 2.2 none 1.3 
v72-1-17-(16-1) 1.0 none 1.4 
v72-1-17-(16-2) 2.0 none 1.4 
v72-1-17-(17) 2.7 none 1.5 
v72-1-17-(18) 4.7 
2.3±1.4 
none 1.5 
1.5±0.1 
v71-16-(8-1) 6.5 miliary, few 2.3 
v71-16-(8-2) 8.6 miliary, few 2.2 
v71-16-(9-1) 10.0 miliary, multiple 3.8 
v71-16-(9-2) 7.5 none 1.8 
v71-16-(10-1) 3.5 none 1.2 
v71-16-(10-2) 4.5 
6.8±2.5 
none 1.7 
2.2±0.9 
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lung samples were carried out as before and confirmed the macroscopical examination (Fig. 
8). 
 
Fig. 8: CD44vk.d. cells exhibit a reduced settlement in the lung   
Ifp injections of BDX rats. Animals were killed, dissected and lungs were analyzed. Macroscopic 
photographs of whole lungs and imunohistological analysis of sectioned lung samples, stained for 
CD44v6 (A2.6) and C4.4A (C4.4) as a tumour marker are shown. A. In vivo metastasis assay #1, 
showing ASMLwt, mock and CD44vk.d. clones. B. In vivo metastasis assay #2, showing one rescue 
clone (v71-14rescv6/7).  
 
The stability of the k.d. and the restored CD44v expression was reconfirmed by re-
cultivation of tumour cells from the lungs or lymph nodes of the injected clones. After lysis, 
SDS-PAGE and western blotting, blots were stained for CD44v6 (A2.6) and EpCAM (D5.7) 
as loading control. This assay clearly demonstrates the stable down-regulation of variant 
CD44 in the established clones and the restored CD44v6/v7 expression in the rescue clone 
(Fig. 9).  
       A  
                      
             
 
B 
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Tab. 3: Restored CD44variant expression is able to rescue the metastatic capacity of 
ASML in part 
tumour burden 
prim. tumour + lymph nodes  lung  
 
injected construct-(animal) 
tumour mass in 
cm3 
average morphology weight 
in g 
average 
mock9-(1-1) 9.0 miliary, confluent 8.7 
mock9-(1-2) 5.7 miliary, confluent 6.2 
mock9-(2-1) 4.5 miliary, confluent 4.4 
mock9-(13) 6.3 miliary, confluent 4.8 
mock9-(15-1) 8.7 miliary, confluent 5.2 
mock9-(14-2) 7.2 
7.0±1.9 
miliary, confluent 6.5 
6.0±1.6 
v71-14-(4-1) 4.5 none 1.5 
v71-14-(4-2) 2.3 none 1.3 
v71-14-(3-1) 3.7 none 1.4 
v71-14-(3-2) 4.1 none 1.2 
v71-14-(5) 2.0 none 1.3 
v71-14-(14) 3.4 
3.3±1.0 
none 0.9 
1.3±0.2 
v71-14rescv6/v7#12-(10-1) 10.3 miliary, confluent 3.0 
v71-14rescv6/v7#12-(11-1) 11.2 miliary, multiple 2.5 
v71-14rescv6/v7#12-(11-2) 6.3 miliary, few 2.1 
v71-14rescv6/v7#12-(12-1) 1 none 1.5 
v71-14rescv6/v7#12-(12-2) 2.2 miliary, few 1.8 
v71-14rescv6/v7#12-(17-1) 7.3 
6.2±4.0 
miliary, few 1.6 
2.1±0.6 
In vivo metastasis assay #2. Ifp injections of BDX rats with mock, one CD44vk.d. clone (v71-14) and 
two v71-14 rescue clones. Animals were killed and dissected after 60 days and tumour burden is 
given as sum of primary tumour and lymph nodes. The mean value for each group is shown. Lungs 
were macroscopically examined and the weight is given as an indication for tumour burden of the 
lung. The second rescue clone (v71-14rescv4-v7#8) did not grow in vivo and is not included in the 
table.  
 
 
Fig. 9: Knocked down and restored expression of CD44v remained stable during the 
animal experiments 
Western blot analysis on re-cultivated tumour cells from injected animals stained for CD44v6 (A2.6) 
and EpCAM (D5.7) as loading control. A. All tested k.d. tumour samples still show the same level of 
down-regulated CD44v. Cultured k.d. (v71-16) and mock cells are shown as control. B. All tested 
tumour samples of the rescue clones still show restored CD44v6/v7 expression. LN lymph node.  
A        B 
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2.3  Characterization of knock-down cell lines in vitro 
2.3.1  CD44vk.d. cells show no phenotypic changes 
 
Cells were grown for 24 hours in 6-well plates. Microscopic analysis revealed no changes in 
cell shape or growth behavior. All clones display the same rounded cell shape without visible 
spreading. ASMLwt and CD44vk.d. cells do not form a dense monolayer with tight cell-cell 
contacts, but rather detach from the ground before reaching complete confluency (Fig. 10). 
The same accounts for the rescue clones. One rescue clone is shown as representative 
example.  
 
Fig. 10: The phenotype of CD44vk.d. clones is not changed 
Microscopic analysis of wt ASML, mock, CD44vk.d. clones and one rescue clone, cultured for 24 
hours.  
 
2.3.2  CD44vk.d. cells show no altered growth behaviour 
 
As the k.d. clones revealed different growth in vivo, the proliferative capacity was compared 
in vitro. Proliferation of wt and knock-down cells was monitored for three days, using either 
3H thymidine incorporation (data not shown) or staining with crystal violet. Both assays 
revealed no significant changes in proliferation rates between the wt and knock-down cells, 
irrespective of cells being grown in the presence of 10% FCS or under low serum conditions 
(0.5% FCS) (Fig. 11). Moreover, colony formation in soft agar, reflecting the ability of 
anchorage-independent growth, a hallmark of metastatic cells, did not show any significant 
changes. All clones revealed a high colony-forming efficacy of 90-95% (Tab. 4).  
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Fig. 11: Proliferation of CD44vk.d. clones is not altered 
Proliferation was monitored for 48h and quantified by crystal violet staining. A. Proliferation in 
medium supplemented with 10% FCS. B. Proliferation in medium supplemented with 0.5% FCS.  
 
 
Tab. 4: Soft agar colony formation of wt ASML, mock and CD44vk.d. clones 
clone colony forming efficacy 
ASML wt 91% +/- 4% 
mock #9 93% +/- 3% 
v7 1-14 90% +/- 5% 
v7 1-16 95% +/- 4% 
v7 2-1-17 89% +/- 6% 
100 and 1000 cells of ASMLwt, mock and CD44vk.d. clones were seeded in RPMI/10%FCS 
containing 0.5% agar. Colonies were counted after 4 weeks. The mean colony-forming efficacy is 
shown.   
 
2.3.3  CD44vk.d. cells do not differ in MMP2 and MMP9 expression 
 
In order to invade adjacent tissues, tumour cells have to degrade extracellular matrix barriers, 
which is often achieved by up-regulation of degrading enzymes like MMPs. To test if down-
regulation of CD44 variants is accompanied by decreased MMP expression, MMP2 and 
MMP9 secretion into the supernatant was tested by a Gelatinease assay. Ten times 
concentrated conditioned cell culture supernatant of wt, mock and k.d. cells was subjected to 
SDS-PAGE, containing Gelatine as a substrate. After completion of the run gels were stained 
with Coomassie (Fig. 12). Enzymatic activity was visualized as unstained bands that reflect 
           A          B 
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the pro-forms of MMP2 and MMP9. No significant differences were observed between the 
clones.  
 
Fig. 12: MMP2 and MMP9 expression of wt ASML, mock and CD44vk.d. clones  
Gelatine zymography of concentrated cell culture supernatants. Unstained bands correspond to Pro-
MMP2 and Pro-MMP9 expression.  
 
 
2.3.4  ASMLwt cells but not CD44vk.d. cells aggregate in stromal cell culture 
 supernatant 
 
As lymph nodal spread is significantly reduced in CD44vk.d. cells, it was tested, if ASML 
cells interact with lymph node stromal cells and if this interaction is impaired in the k.d. cells. 
Adhesion to monolayers of the lymph node stromal cell lines ‘ST-A4’ and ‘ST-B12’ or an 
immortalized lung fibroblast cell line did not reveal any affinity of ASML (data not shown). 
Instead it was noticed that ASML cells clumped and formed cell agglomerates when added to 
the stromal cells. This observation was tested subsequently with conditioned cell culture 
supernatant of the three mentioned stromal cell lines. Only wt and mock cells formed huge 
agglomerates in the supernatant within minutes, while CD44vk.d. cells did not clump at all or 
formed only very small cell clusters. The ability to form agglomerates was completely 
reestablished by the restored CD44v expression in the rescue clones (Fig. 13).  
 
 
 
 
Results 
 36 
Fig. 13: Agglomerate formation in conditioned cell culture supernatant of stromal cells 
Microscopic analysis of agglomeration of ASMLwt, mock, k.d. and rescue clones in conditioned cell 
culture supernatant of immortalized lung fibroblasts (A) and the lymph node stromal cell line ST-A4 
(B). ASMLwt cells in RPMI medium are shown as control.  
 
As hyaluronic acid (HA) is known to crosslink CD44 on the surface of cells and stromal cells 
are known to produce HA in large amounts, it was tested if the cell clumping was due to 
CD44 cross-bridging by HA in the supernatant. Supernatant was treated with hyaluronidase 
(1mg/ml) for 2 or 5 hours and agglomeration was monitored as before, heat-inactivated 
hyaluronidase served as a control. Indeed cell clumping was abrogated by hyaluronidase 
treatment in a time dependent manner (Fig. 14B). Likewise, addition of 1mg/ml HA to 
normal RPMI medium was able to induce agglomerate formation of ASML cells (Fig. 14A), 
demonstrating that the observed clustering is likely due to bridging of cell surface CD44 by 
HA.  
 
 
 
 
 
 
    
    A 
 
    B 
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Fig. 14: Influence of hyaluronic acid on agglomeration of ASML cells  
A. Addition of HA to normal RPMI medium is able to induce agglomeration of ASMLwt cells. B. 
Stromal cell culture supernatant was treated with hyaluronidase for 2 or 5 hours, which abrogates 
aggregation. Heat inactivated hyaluronidase was used as a control.  
 
2.3.5  ASMLwt cells produce an adhesive matrix, which is impaired in the 
 CD44vk.d.  
 
ASML cells show a very limited ability to bind to matrix components, like 
fibronectin, laminin or collagen, while cultivated cells strongly attach to the plastic flasks. 
This feature is reduced in CD44vk.d. cells as noted by different sensitivities to trypsin 
treatment. To test for differences in adhesion, conditioned cell culture supernatant of 
ASMLwt cells was coated to plastic and used for adhesion assays. ASMLwt and CD44vk.d. 
cells show rapid adhesion to the coated supernatant, indicating that adhesion is not impaired 
in the k.d. (data  not shown).  
The supernatant of the knock-down cells was tested for adhesive properties after 
coating. Interestingly, a dramatic reduction was observed. Figure 15A shows reciprocal 
crisscross adhesion to matrices of wt cells, a mock clone and the three knock-down clones. 
All 5 clones adhere rapidly to the wt and mock derived matrix, while adhesion to the matrices 
produced by either of the knock-down clones is strongly impaired for all cells. To test if 
adhesion is induced by a soluble or deposited factor, cells were cultured in 24-well plates for 
24 hours and detached by either trypsin or EDTA treatment. The plates were used for 
adhesion assays as described above. Only EDTA treated plates were able to promote 
adhesion (data not shown). Using this approach wt and knock-down cells were compared for 
their ability to deposit an adhesion promoting matrix. Indeed, the knock-down matrix was 
          
          A           B 
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clearly less capable of promoting adhesion than the wt matrix. However, the difference was 
less pronounced than for the conditioned supernatant (Fig. 15B). These results show that the 
loss of variant CD44 in ASML cells leads to an impaired ability to produce an adhesive 
matrix.  
 
Fig. 15: Adhesion to coated supernatant and deposited matrix of wt ASML and k.d. 
cells 
A. Adhesion assay on coated supernatant of wt ASML and k.d. clones. Relative adhesion of each line 
to the different matrices is shown. Adhesion of wt ASML to wt matrix was set to 100%. B. Adhesion 
of ASMLwt to deposited matrices of the different clones. Deposited matrix was prepared by removal 
of cells through EDTA treatment.  
 
 
In order to investigate, whether this matrix defect is indeed due to the loss of CD44, 
the rescue clones displaying restored expression of CD44v4-v7 or CD44v6/v7 were used for 
matrix production and compared to the parental knock-down clone. As expected, restoration 
of either CD44 isoform was able to restore the matrix production significantly, but without 
reproducing the full adhesive properties of the wt matrix (Fig. 16). In summary, loss of 
variant CD44 in ASML cells leads to an impaired ability to generate an adhesion-promoting 
matrix, which is deposited on the plastic and secreted into the supernatant. Restoring 
CD44variant expression is able to restore this matrix production in part.  
 
       A                  B 
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Fig. 16: Restoring CD44v expression rescues matrix production 
Adhesion assay of ASMLwt cells to coated supernatant of ASMLwt, v71-14 and v71-14rescue 
clones. Adhesion of ASMLwt cells to wt matrix is set to 100%.  
 
2.3.5.1 Adhesion promoting components are secreted 
 
To verify that the components mediating adhesion are secreted factors, and not present on 
membrane particles, like exosomes or membrane fragments, ultracentrifugation (100000g) 
was performed, which should precipitate all membrane particles present in the supernatant. 
The resuspended pellet and the supernatant were tested for adhesive properties after coating 
to plastic. Only the supernatant was able to promote adhesion of ASML cells (Fig. 17A). The 
tetraspanin D6.1A was used as exosomal marker (Wubbods et al., 2003) and was completely 
removed from the supernatant by centrifugation, while shed CD44 was present in the 
supernatant, demonstrating that the separation procedure was successful (Fig. 17B).  
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Fig. 17: Ultracentrifugation of cell culture supernatant 
100000g centrifugation from concentrated supernatant of wt ASML A. Adhesion assay on coated  
supernatant and the resuspended pellet. B. Western blot control for shed CD44v6 (A2.6) and for 
D6.1A (D6.1) as an exosomal marker. 
 
2.3.5.2 The secreted matrix contains HA, collagen and laminin 
 
As CD44 is known to be involved in the assembly of pericellular matrices through 
anchoring hyaluronic acid, the matrix was tested for sensitivity to hyaluronidase treatment as 
well as for collagenase treatment. Conditioned supernatant was treated with different 
concentrations of hyaluronidase or collagenase either before or after coating to plastic and 
adhesion assays were performed as described. Heat-inactivated enzymes were used as 
controls (Fig. 18). While hyaluronidase treatment after coating did not alter the adhesive 
properties, it did destroy the ability to promote adhesion, when the supernatant was treated 
prior to coating (Fig. 18B). This indicates that HA is used as a scaffold for other matrix 
components rather than as adhesive substrate and implicates that adhesion itself is not 
mediated by CD44, which goes along with the finding that the k.d. clones do not display an 
impaired adhesion to the wt matrix. In contrast, collagenase treatment did abrogate the 
adhesive properties of the matrix irrespective if the supernatant was treated before or after 
coating (Fig. 18A). In summary, these results indicate that HA is needed for the assembly of 
other matrix components and that the rapid adhesion of ASML cells is mediated via binding 
to collagen.  
 
 
     A       B 
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Fig. 18: Hyaluronidase and collagenase treatment disrupts the adhesive properties of 
the supernatant 
Supernatant of wt ASML was treated with different concentrations of collagenase after coating (A) 
and hyaluronidase before or after coating (B). Adhesion assays were performed with ASMLwt cells 
as described earlier.  
 
 
The adhesive portion of the secreted matrix is between 600 and 4000kDa in size  
 
To further characterize the composition of the secreted matrix, conditioned 
supernatant was collected and concentrated 40 times through a ‘vivaspin’ column. The 
concentrate was size separated by gelfiltration using different pore sizes. Fractions were 
collected and used for coating to 24-well plates. The void volume of the column was defined 
by blue dextrane. Adhesion assays were performed and revealed that the fractions promoting 
adhesion were still within the void volume, when ‘Superdex200’ beads were used (Fig. 19A), 
but were within the separation range of ‘CL6B’ beads (Fig. 19B). This indicates that the 
components promoting adhesion are larger in size than roughly 600 kDa, (size exclusion of 
Superdex200) but smaller than 4000 kDa (size exclusion of CL6B). The adhesive fractions of 
wt cells after chromatography were compared to the corresponding fractions of the knock-
down cells using silver staining. However, protein content was low in general and no visible 
differences could be observed (data not shown).  
 
A      B 
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Fig. 19: Size exclusion chromatography of wt and k.d. supernatant 
Concentrated supernatants of wt ASML and v71-16 k.d. cells were size fractionated by 
chromatography on Superdex200 (A) and CL6B (B) sepharose columns.  Fractions were coated to 
plastic and used for adhesion assays. The void volume was defined by blue dextrane.  
 
 
In order to identify components of the matrix mediating adhesion, CL6B fractions 
were subjected to SDS-PAGE and western blotting and probed with different antibodies. 
Shed CD44 was not present in the fractions promoting adhesion. In contrast, laminin was 
present, although not exclusively in the adhesive fractions and no difference in the laminin 
distribution was observed between the wt and the knock-down fractions (Fig. 20).  
 
 
 
 
A 
 
 
 
B 
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Fig. 20: Western blot analysis for CL6B-fractionated conditioned supernatant 
Western blot analysis of fractionated supernatants. Concentrated supernatants of wt ASML and a 
CD44vk.d. clone (v71-16) were size fractionated by chromatography on CL6B sepharose columns. 
Fractions including the adhesive fractions (see Fig. 19) were subjected to SDS-PAGE and stained for 
CD44v6 (A2.6) and laminin (polyclonal serum recognizing several laminins).  
 
2.3.5.3 Adhesion to the matrix is mediated by β1 integrin 
 
The observation that trypsin treatment destroyed the deposited matrix but EDTA 
treatment left the matrix unaltered, together with the finding that collagen and not HA seems 
to be involved in the adhesion process suggests that adhesion of ASML to their own matrix 
could be mediated by integrins. In line with this, addition of EDTA during adhesion 
abrogated attachment of the cells, arguing for Ca2+ dependent adhesion (data not shown). To 
further test this hypothesis different antibodies were tested for their ability to block adhesion. 
For this purpose cells were pre-incubated with different integrin antibodies and adhesion was 
performed as before. Figure 21 shows that only a β1 integrin antibody blocked adhesion in a 
concentration dependent manner, while all other antibodies, including anti CD44, had no 
influence on adhesion. Anti α6β1 induced cell aggregation and could therefore not be used 
for blocking experiments. ASML cells do not express α1, α4 and α5 integrin chains (data not 
shown). Pre-incubation of the coated matrix with an anti laminin polyclonal serum (reacting 
with several laminins) did not interfere with adhesion. Therefore it seems likely that initial 
adhesion of ASML cells to their own matrix is mediated by a β1 integrin binding to matrix 
bound collagen, even though the specific type of collagen and the integrin α chain could not 
be identified.  
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Fig. 21: Interfering with β1-integrin blocks adhesion to the secreted matrix 
ASMLwt cells were pre-incubated with different antibodies and used for adhesion assays to wt ASML 
matrix. For laminin blocking, the coated matrix was pre-incubated with anti laminin polyclonal serum 
instead.  
 
 
2.3.6  CD44vk.d. cells lack a secreted 180 kDa protein 
 
To identify components present in the supernatant that might be responsible for the 
matrix defect, silver staining of concentrated conditioned supernatant from wt and k.d. cells 
was performed and revealed a 180 kDa protein, which was greatly reduced in all three k.d. 
clones (Fig. 22A). The protein was subjected to mass spectrometric analysis and was 
identified as ‘complement component 3’ (C3), an element of the innate immune system. The 
mass spectrometry result was verified using a specific antibody and confirmed, that wt and 
mock ASML cells secrete complement component 3 and that this is greatly reduced in the 
k.d. cells. Concentrated conditioned supernatant was subjected to SDS-PAGE under reducing 
conditions, which leads to separation of C3 into two subunits C3α and C3β (Fig. 22B). 
However, the restored CD44 expression in the rescue clones failed to restore the secretion of 
complement component 3, therefore, it can not be ruled out that this is an unspecific off-
target effect of the RNAi approach.  
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Fig. 22: Differential protein expression of wt and k.d. clones  
A. Silver staining of concentrated supernatant of wt and k.d. clones reveals a differentially expressed 
180 kDa protein, marked by an arrow. B. Western blot analysis after SDS-PAGE under reducing 
conditions confirms differential expression of complement component 3, which is not restored in the 
v71-14 rescue clones.  
 
 
2.3.7  CD44vk.d. cells exhibit a reduced resistance to apoptotic triggers 
 
Apoptosis resistance is a hallmark of metastatic tumour cells and ASML cells are 
highly resistant to induction of apoptosis (Matzku et al., 1985). In order to compare 
susceptibility to apoptosis of wt and CD44vk.d. cells, resistance to the chemotherapeutic drug 
cisplatin and to γ-irradiation was evaluated. Cells were treated with different concentrations 
of cisplatin for three days and survival was monitored by MTT staining. For γ-irradiation 
adherent cells were irradiated with different doses. ASML cells display high drug and 
radiation resistance and mock transfectants showed comparable levels, while all three 
CD44vk.d. clones displayed significantly higher susceptibility to both kinds of apoptotic 
triggers (Fig. 23). The IC50 for cisplatin was about 45µg/ml for wt and mock and about 5-
10µg for all three CD44v k.d clones. For γ-irradiation the IC50 for the k.d. clones was at 250 
Gy, while 600Gy killed only about 40% of wt and mock cells. The restored CD44 expression 
in the rescue clones was not able to reestablish apoptosis resistance (Fig. 24).  
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Fig. 23: CD44vk.d. clones are more susceptible to apoptotic triggers  
Wt ASML and k.d. clones were treated with different concentrations of cisplatin (A) or subjected to 
different doses of γ-irradiation (B). Survival was monitored after three days by MTT staining.  
 
 
Fig. 24: Restoring CD44 expression does not rescue the apoptosis resistance of 
CD44vk.d. clones 
Mock, k.d. and rescue clones were treated with different concentrations of cisplatin (A) or subjected 
to different doses of γ-irradiation B). Survival was monitored after three days by MTT staining.  
 
 
2.3.7.1 Apoptosis resistance is increased by elongated pre-cultivation prior to irradiation 
 
In order to test an influence of the matrix produced by ASML cells on apoptosis 
resistance, cells were seeded and pre-incubated for either 15 or 48 h before irradiation. The 
longer cultivation clearly leads to an enhanced resistance. Although the k.d. cells also display 
higher resistance, they do not reach the level of the wt cells (Fig. 25).  
 A        B 
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Fig. 25: Influence of cultivation period on resistance to radiation 
Cells were cultivated for 15 (A) or 48 hours (B) prior to γ-irradiation. Survival was monitored after 
three days by MTT staining.  
 
 
Higher susceptibility to apoptosis of CD44vk.d. cells is not reversible by wt matrix 
To test a contribution of the produced matrix to apoptosis resistance, wt, k.d. and 
rescue cells were seeded onto wt matrix, which had been prepared by EDTA removal of wt 
cells. Only the wt cells showed a slight increase in resistance, while neither the k.d. clones 
nor the rescue clones were able to make use of the wt matrix in terms of enhanced apoptosis 
resistance (Fig. 26).  
 
Fig. 26: Wt matrix does not rescue apoptosis resistance of CD44vk.d. cells 
ASMLwt, k.d. and rescue clones were seeded on wt matrix and subjected to different doses of γ-
irradiation. Survival was monitored after three days by MTT staining.  
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2.3.7.2 PI3K-Akt, rather than MAPK signalling is involved in apoptosis resistance of  
 ASML cells 
 
The two main pathways influencing apoptosis resistance described to be influenced 
by CD44 are the MAPK pathway and the PI3K-Akt pathway. Therefore, the influence of 
specific inhibitors to these pathways was tested for γ-irradiation-induced apoptosis. ASMLwt 
and CD44vk.d. cells revealed a marked increase in susceptibility to γ-irradiation when treated 
with the PI3K specific inhibitor LY294002, while an inhibitor of the MAPK pathway (MEK 
1/2 inhibitor) had no influence at the applied dose (Fig. 27A, Fig. 28A).  
 
PI3k-Akt signalling is impaired in CD44vk.d. cells 
 
PI3K and Akt inhibitors are known to induce apoptosis in some cancer cells on their 
own, this was also apparent in the LY294002 treated, but not irradiated controls (Fig. 28A). 
Therefore, ASMLwt and CD44vk.d. cells were tested for their tolerance for these inhibitors 
at high concentrations. Using the same survival assay as for cisplatin treatment, adherent cells 
were treated with different concentrations of either LY294002 or Akt II inhibitor and tested 
for survival after three days. Wt and k.d. cells display high tolerance for both inhibitors. 
However, the IC50 for wt and mock cells is 125µM for the PI3K inhibitor and 40µM for the 
AKT II inhibitor, while k.d. cells show the same degree of apoptosis induction already at 
50µM and 15-20µM respectively (Fig. 28B+C). This clearly demonstrates an impaired PI3K-
Akt signalling in the CD44vk.d. clones compared to wt cells. However, the rescue clones 
displayed the same reduced tolerance as the k.d. clones. One rescue clone is shown as 
representative example. The MEK1/2 inhibitor did not induce apoptosis even at very high 
doses in none of the clones, which excludes a CD44 mediated involvement in MAPK 
signalling (Fig. 27B).  
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Fig. 27: Interfering with MAPK signalling has no influence on apoptosis resistance of 
ASML cells 
A. ASMLwt (left panel) and CD44vk.d. cells v72-1-17 (right panel) were treated with a MEK1/2 
inhibitor at 10µM and irradiated with 300 Gy. Survival was monitored after 3 days by MTT staining. 
B. ASMLwt, mock and CD44vk.d. cells were treated with different concentrations of the MEK1/2 
inhibitor. Survival was monitored after three days by MTT staining.  
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Fig. 28: Interfering with the PI3k-Akt pathway leads to decreased apoptosis resistance 
and PI3kinase-Akt signalling is impaired in CD44vk.d. cells 
A. ASMLwt and CD44vk.d. cells (v71-14) were treated with the PI3K specific inhibitor LY294002 at 
50µM and irradiated with 300 Gy. Survival was monitored after 3 days by MTT staining. B. + C. 
ASMLwt, mock, CD44vk.d. and rescue cells were treated with different concentrations of LY294002 
(B) or an Akt II specific inhibitor (C). Survival was monitored after three days by MTT staining.  
 
 
In order to identify differences in downstream signalling between wt and CD44vk.d. 
cells, several anti- and proapoptotic molecules were evaluated. Upon cisplatin treatment with 
10µg/ml for 24h, cells were lysed, subjected to SDS-PAGE, blotted and tested for expression 
levels. Phosphorylation of Akt is lowered in the k.d. cells upon drug treatment, while levels 
stay unaltered in the wt and mock cells. The same was observed for the antiapoptotic 
molecule Bcl-2, which is only down-regulated in the CD44vk.d. clones after treatment. In 
correlation with the inhibitor data, phosphoERK levels stay unchanged upon cisplatin 
treatment in all clones (Fig. 29A+B).  
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CD44v are able to trigger activation of Akt 
 
Restoring CD44v expression in the rescue clones did not compensate for the impaired PI3K-
Akt signalling of CD44vk.d. cells. Therefore, the influence of CD44v on the activation of this 
pathway was tested by crosslinking surface CD44v on ASMLwt cells. Cells were seeded on 
plates, coated with anti CD44v6 (A2.6) or BSA as control and lysed after 2h of incubation. 
After SDS-PAGE and western blotting, phosphorylation of Akt was evaluated. An increase 
upon crosslinking of CD44v was observed (Fig. 29C). This demonstrates that CD44v can 
trigger activation of Akt in ASML cells and promote survival in this way.  
 
Fig. 29: Reduced survival signalling in CD44vk.d. cells and activation of Akt by 
crosslinking CD44v 
A.+ B. Western blot analysis for untreated and cisplatin (10mg/ml) treated wt and k.d. cells. Cells 
were lysed 24h after treatment. A. Akt becomes dephosphorylated in the CD44vk.d., but not in the wt 
cells after drug treatment. Total Akt is used as loading control. Bcl-2 becomes down-regulated only in 
the CD44vk.d. clones, but remains unaltered in ASMLwt and mock cells upon cisplatin treatment. 
EpCAM (D5.7) is used as loading control. B. pERK staining does not change upon drug treatment. 
EpCAM staining (D5.7) is used as loading control. C. Phosphorylation of Akt can be induced by 
CD44v crosslinking. ASMLwt cells were seeded on plates coated with anti CD44v6 (A2.6) or BSA as 
control and lysed after 2h. Total Akt is used as control.  
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3.  Discussion 
 
The formation of metastases is the final stage of tumour progression and treatment is 
still inefficient. Only very recently new therapeutic approaches gained access into clinical 
application. For example monoclonal antibody therapies, such as ‘Herceptin’ targeting the 
HER2 receptor in order to prevent breast cancer metastasis. The basis of these new strategies 
is a molecular understanding of the mechanisms underlying the process of tumour 
progression. However, many aspects of metastasis formation remain poorly understood.  
The involvement of CD44 in tumour progression and particularly in the development 
of metastases has been studied for many years, and multiple functions for CD44 and its 
variant isoforms have been identified (Naor et al., 1997; Marhaba and Zoller, 2004). In this 
work the role of variant CD44 in different aspects of the metastatic process was investigated 
in ASML cells, a highly metastatic pancreatic adenocarcinoma. The pSuper RNAi system 
was used to create stable and variant specific CD44 k.d. cells, which were characterized for 
their metastatic capacities in vivo and in vitro. The contribution of CD44v as a cell-cell and 
cell-matrix adhesion molecule was studied during the multistep process of metastasis 
formation with special emphasis on interactions with the surrounding. In this respect, several 
CD44v-mediated features supporting the settlement and survival of tumour cells during 
lymphatic spread were identified. This highlights the role of CD44 as a multi functional 
player during the course of metastasis formation through interactions with neighbouring cells 
and the microenvironment, but also by actively organizing the ECM and finally functioning 
as signalling molecule, supporting cell survival as well.  
 
Loss of CD44 by stable and variant specific knock-down results in reduced metastatic 
capacity of ASML cells 
The BSp73 cell system comprises of two sublines of the same primary tumour, which 
display different metastatatic potential. The two most abundant CD44 variants expressed by 
the highly metastatic ASML cells are v4-v7 and v6/v7, and these isoforms were demonstrated 
to confer metastatic capacity to otherwise only locally growing AS cells. In order to confirm 
an essential contribution of these isoforms on the metastatic growth of ASML cells, RNAi 
constructs were designed to target both isoforms. Two out of three constructs proved to be 
efficient in down-regulating CD44v expression on ASML cells. Selection and recloning 
yielded stable clones displaying only hardly detectable residual CD44v expression. Three 
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clones were established with ‘pSuper-v7’ (subsequently denoted ‘knock-down’ or ‘k.d.’ 
cells), while no stable clones could be raised with the ‘pSuper-v6/v7’ construct, which would 
have allowed to easily control construct-specific off-target effects. To confirm any 
phenotype, arising in the knock-down cells, clones with restored expression of one of the 
dominant CD44v isoforms were successfully established from one of the k.d. clones (denoted 
rescue cells). However, the expression level of the CD44v4-v7 rescue did not achieve the wt 
level.  
Upon intra-footpad application, ASML cells spread exclusively through the 
lymphatics. They display only little local tumour growth, but readily settle in the lymph 
nodes and the lung, where they form miliary metastastic lesions (Matzku et al., 1983). All 
three CD44v knock-down clones displayed reduced metastatic growth in vivo with severely 
impaired settlement in the lung. For unknown reasons the injected CD44v4-v7 rescue clone 
did not grow in vivo, probably due to a defect, acquired during in vitro culture, which might 
have allowed the immune system to eliminate the tumour cells. However, five out of six 
animals, injected with the CD44v6/v7 rescue clone displayed enhanced metastasis formation. 
Especially when compared to the parental k.d. clone ‘v71-14’, this clearly demonstrates a 
restored metastatic activity, although the massive tumour burden of the wt was not achieved. 
The knock-down and the rescued CD44v expression remained stable throughout the in vivo 
experiment, as confirmed by western blotting on re-cultivated tumour cells and by 
immunohistology on lung sections. In summary, stable and variant-specific loss of CD44 
expression in ASML does interfere with the lymphatic spread and lung settlement of these 
cells. However, more rescue clones will be required to ensure statistical significance of the 
restored metastatic capacity. It has to be mentioned in this respect, that complement 
component 3 (C3) was found to be differentially expressed between ASMLwt and CD44vk.d. 
cells, but could not be restored in the rescue clones, which might argue for an unspecific off-
target effect. As C3 is an important molecule of the innate immune system, it cannot be ruled 
out that this might have affected the in vivo experiment. On the other hand, this does not 
seem very likely, taken into account that the described rescue clone did restore the metastatic 
capacity of the k.d., irrespective of the unrestored C3 expression.  
 
CD44v knock-down cells display no phenotypic differences or altered growth characteristics 
In order to identify defects, which could be causally related to the reduced metastatic 
growth of ASML CD44vk.d. cells in vivo, the cells were studied in vitro. The impaired in 
vivo growth is not due to a generally reduced proliferation rate, which was demonstrated by 
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proliferation assays under high and low serum conditions, nor to a reduced anchorage-
independent growth, as shown in soft agar assays. Both, ASMLwt and CD44vk.d. cells are 
not significantly affected by low serum conditions, as the proliferation rate was only very 
slightly reduced. Both revealed a very high colony-forming efficacy of 90-95% in soft agar, 
demonstrating high anchorage-independence. Another way, how CD44 could promote 
metastasis formation is by up-regulating matrix degrading enzymes to promote invasion. 
MMP2 and MMP9 are capable of degrading collagen IV, the major collagen of basement 
membranes, and several studies link hyaluronic acid (HA) and CD44 to MMP2 and MMP9 
secretion or activation (Zhang et al., 2002; Isnard et al., 2003; Murray et al., 2004). CD44 can 
recruit MMP9 to the cell surface, leading to collagen IV degradation and invasion (Yu et al., 
1999). Gelatine zymography demonstrated low amounts of secreted MMP2 and MMP9 by 
ASML, as enzymatic activity was only detectable after concentration of the supernatant. This 
is in line with the relatively low ‘aggressive’ growth of ASML cells in vivo, which rather 
grow by displacement than by destruction of host tissue (Matzku et al., 1983, 1985; Raz et 
al., 1986). No significant differences in MMP2 and MMP9 secretion could be observed 
between wt and CD44vk.d. cells. It can’t be ruled out though, that other MMPs are 
deregulated in the k.d. cells, which might favour invasive growth. However, the lymphatic 
spread of tumour cells might require different features and degrading basement membranes 
might be less mandatory for entrance to the lymphatic vasculature than into blood vessels. 
The lymphatic spread of tumour cells is still incompletely understood, but an interesting 
aspect is the involvement of members of the VEGF growth factor family and chemokines in 
this process. Tumour cells express chemokine receptors on their surface, enabling them to 
migrate in a chemotactic manner to lymphatic vessels expressing the appropriate ligands. For 
example, the chemokine receptors CXCR4 and CCR7 are involved in metastasis formation of 
breast cancer (Muller et al., 2001) and melanoma cells (Wiley et al., 2001). A possible role 
for chemokine receptors in the lymphatic spread of ASML cells was tested by RT-PCR for 
CXCR4 and CCR7 expression. However, neither ASML nor AS cells express CXCR4 or 
CCR7 (data not shown). Therefore, an implication of chemokine receptor expression on the 
metastatic spread of ASML cells seems rather unlikely.  
 
Agglomeration in HA-rich medium is abrogated in CD44vk.d. cells 
ASML cells metastasize via the lymphatics to the lung. As the proliferative capacities 
of CD44vk.d. cells are unaltered in vitro, the stromal surrounding of the lymph nodes or the 
lung might promote tumour growth. When potential influences of stromal cell lines on 
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ASML cells were evaluated, it was noted, that conditioned cell culture supernatant of lymph 
node stromal cells or of lung fibroblasts was able to induce agglomeration of wt, but not of 
k.d. cells. This feature was completely rescued by restoring CD44v expression. Cell 
clumping was due to HA-mediated cross-bridging of CD44 molecules on the cells, because it 
could be induced by high concentrations of HA and was abrogated by hyaluronidase 
treatment. CD44vk.d. cells are therefore unable to aggregate in stromal supernatant due to the 
lack of receptor expression. CD44-mediated cell aggregation has been shown to enhance lung 
metastasis after i.v. injection (Birch et al., 1991, Weber at al., 1996). Thus, it is interesting to 
note that stromal cells, present at places of major tumour growth of ASML, are capable of 
producing HA in amounts suitable to induce cell clumping, which could lead to reduced 
motility and enhanced settlement and thereby promote tumour cell growth. Tumour cell 
agglomeration has been described to facilitate settlement of tumour cells (Mansury et al., 
2002; Glinsky et al., 2003) and the lack of cell aggregation of CD44vk.d. cells may account 
for reduced metastatic growth.  
 
Impaired matrix production by CD44vk.d. cells 
ASML cells adhere very slowly to plastic or matrix components and do not spread, 
irrespective of the substrate (BenZe’ev et al., 1986). Instead, they display a rounded cell 
shape, attach very tightly during cultivation and can only be detached by harsh trypsin 
treatment or very long EDTA exposure. This attachment was reduced in the k.d. cells. When 
conditioned supernatant of wt and k.d. cells was coated to plastic, both, wt and k.d. cells 
adhered rapidly to the wt and mock matrix, while the k.d. matrix was clearly less adhesive. 
Thus it seems likely, that matrixproduction is impaired in the CD44vk.d. cells. This was true 
for matrix components secreted into the supernatant and for matrix deposited onto the plastic. 
The rescue clones showed a partially restored matrix production, but could not fully 
reproduce the adhesive properties of the wt matrix. The components of the matrix are 
secreted, which could be demonstrated by ultracentrifugation. Hyaluronic acid is most likely 
needed for proper assembly of the matrix, as hyaluronidase treatment prior to coating disrupts 
the adhesive properties, but treatment after coating had no influence. This indicates that 
adhesion of ASML cells is not mediated through CD44-HA interactions, which is confirmed 
by the finding that CD44vk.d. clones do not display impaired adhesion to the wt-matrix. 
Instead, collagenase treatment disrupts the adhesive properties of the matrix in a 
concentration dependent manner, indicating that collagens function as ligands for adhesion. 
When cells were removed by trypsin or EDTA treatment and the deposited matrix was used 
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for adhesion, only EDTA detachment of the cells left the matrix intact, while trypsin 
treatment destroyed the adhesive properties. Adhesion could also be blocked by addition of 
EDTA during the adhesion assay (data not shown), arguing for Ca2+-dependent adhesion. 
Antibody blockade demonstrated that β1 integrins are involved, as pre-incubating the cells 
with anti β1 antibody completely blocked adhesion in a concentration dependent manner. 
ASML cells express different α chains complementing to β1 at high levels, but anti α2 and 
anti α3 were not inhibiting adhesion. Anti α6β1 could not be used for antibody blocking, as 
it induced cell clumping and hindered adhesion in this way (data not shown). Integrins 
usually do not show high ligand specificity, but α2β1 and α3β1 are known to bind collagen 
and other matrix components, while α6β1 shows a higher affinity to laminin. However, 
additional α subunits that were not tested, such as α10β1 and α11β1 were shown to bind 
collagens as well and might be involved in matrix binding of ASML cells.  
Size chromatography under neutral conditions revealed, that the adhesion-mediating 
components of the matrix are between 600 and 4000kDa in size. This corresponds to a 
collagen ligand, when organized as multimer or with other matrix components, or present 
within a HA-lattice. Altered matrix assembly in the k.d. cells may result in a differential 
distribution of matrix components after size fractionation. The fractions were analysed by 
western blotting revealing laminin as a component of the adhesive fractions. However, the 
distribution did not differ in the k.d. matrix. It is possible though, that the resolution of the 
applied chromatography was not sufficient for detecting differences in size distribution, or 
that only the order of matrix components is affected, which does not necessarily alter the size 
of matrix aggregates. However, antibody blocking with a polyclonal serum against laminin 
did not affect adhesion. Therefore, laminin does not seem to mediate the rapid adhesion, but 
is present in the matrix. Shed CD44 is not present within the adhesion-promoting fractions, 
which excludes a mechanism of shedding CD44 to release assembled matrix components. 
The specific collagen involved in adhesion could not be identified, as the available antibodies 
did not function in western blotting. Tumour-stroma interactions are important for the 
pathogenesis of pancreatic cancer, although the matrix production is usually attributed to 
fibroblastic deposition of ECM (Gress et al., 1995), pancreatic cancer cells have also been 
described to produce matrix components including collagens (Lohr et al., 1994). CD44 is 
known to be important for pericellular matrix assembly in chondrocytes, where it functions as 
a HA-anchor (Knudson et al., 2003; Jiang et al., 2002). Particle exclusion assays with 
erythrocytes did not reveal any pericellular accumulation of matrix material by ASML cells 
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grown in vitro (data not shown). It might be possible however, that these cells are capable to 
form a pericellular matrix, when aggregating proteoglycans are added in addition, as shown 
for other cancer cells (Knudson and Knudson, 1991). The matrix of ASML cells is also 
deposited on the culture dish and was even more adhesive when prepared in this way than the 
coated supernatant. Whether the matrix material is actively deposited on the culture dish or 
just passively bound to the plastic remains open. In conclusion, it seems that cell surface 
CD44v is needed for proper assembly of matrix components in ASML cells, which most 
likely is mediated through formation of a HA scaffold. In addition to a HA-anchoring 
function of CD44, collagens might integrate into the matrix directly via binding to CD44, as 
CD44-mediated adhesion to collagen containing matrices was described before (Knutson et 
al., 1996). In chondrocytes, interfering with CD44 cell-matrix interactions results in a ‘matrix 
remodelling’ response, which leads to chondrolysis via up-regulation of proteases and 
enhanced biosynthesis of proteoglycans and HA (Knudson et al., 2000). In this view, it is 
feasible, that also in ASML cells, CD44 interaction with matrix HA is not only important for 
assembly, but might also affect matrix biosynthesis.  
The ability of ASML cells to secrete their own adhesive matrix could promote 
metastatic growth at a secondary site in two ways. First, adhesion is supported, enhancing 
settlement of tumour cells in the lymph nodes and the lung, and second, the matrix could 
support growth or survival. As metastases have to adapt to the new surrounding at a 
secondary site, establishing their own matrix should be supportive. Metastasis formation of 
CD44vk.d. cells may thus be reduced through an impaired ability to generate an adhesive 
matrix.  
 
Impaired apoptosis resistance of CD44vk.d. cells 
Pancreatic adenocarcinomas are aggressive cancers, characterized by invasiveness, 
rapid progression and high resistance to chemo- and radiation therapy (reviewed by Bardeesy 
and DePinho, 2002). Similarly, ASML cells exhibit low susceptibility to apoptotic triggers. 
CD44 is described to be involved in apoptosis resistance and some reports link this feature to 
variant isoform expression (Bates et al., 1998; Wittig et al., 2000; Marhaba et al., 2003). 
Metastasis formation and resistance to apoptosis is closely related to the ECM and the 
microenvironment, known to trigger survival signals. Susceptibility to apoptotic triggers was 
greatly enhanced in ASML CD44vk.d. cells, using the chemotherapeutic drug cisplatin and γ-
irradiation. Because CD44-HA interaction has been described to be involved in apoptosis 
resistance (Toole, 2004) an impact of the secreted ASML-matrix was tested by enabling 
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matrix formation for different periods of time prior to irradiation. Indeed, prolonged 
cultivation increased the apoptosis resistance of both, wt and k.d. cells significantly. 
Moreover, wt cells could gain further protection by seeding on a preformed matrix, 
confirming survival supporting functions of the matrix. However, CD44vk.d. cells did not 
display enhanced resistance on a preformed wt-matrix, arguing for a direct influence of CD44 
on survival signalling upon ECM mediated triggers. Yet, the rescue cells were not able to 
compensate for this, which could have several reasons that will be discussed later. 
 Cells often react to the substrate by changing the expression of adhesion molecules 
and alteration of the expressed integrin repertoire may contribute to tumour progression and 
metastasis formation (Schwartz et al., 1993, Maschler et al., 2005). In pancreatic cancer for 
example, α6β1 was described to influence metastatic behaviour (Vogelmann et al., 1999). 
Integrin signalling is also known to affect survival (Lewis et al., 2002). For example, β1 
integrin binding to ECM components promotes survival by activating PI3K in small-cell lung 
cancer cells (Hodkinson et al., 2006). Islets of Langerhans cells are protected from anoikis 
through β1 ligation with antibodies or by cultivation on collagen IV, which is accompanied 
by an increase of Akt phosphorylation (Pinkse et al., 2006). However, evaluation of 
expression levels of α6β1, α6β4 and the subunits α2, α3 and β1 in ASML cells revealed no 
significant differences, neither between wt and k.d. cells nor upon prolonged cultivation (data 
not shown). However, not all integrin dimers could be tested due to a lack of suitable 
antibodies. Besides integrins, also other molecules involved in cell-matrix interactions and 
contributing to survival could be affected by the matrix defect.  
Irrespective of the protective feature of the produced matrix, CD44 is described to 
interfere with apoptosis in different ways. As ASML CD44vk.d. cells display a reduced 
resistance to drug treatment and irradiation, it seems unlikely that receptor-mediated 
apoptosis is the reason. An involvement of multidrugresistance (MDR) cannot account for the 
observed resistance to radiation as well. Nevertheless, CD44 was shown to influence the 
expression of MDR genes (Misra et al., 2005; Tsujimura et al., 2006), prompting the analysis 
of MDR genes in ASML cells. MRP2 and MRP5 are described to be involved in cisplatin 
transport (Suzuki et al., 2001; Nomura et al., 2005; Oguri et al., 2000), but ASML cells were 
tested negative for both transporters (data not shown). Instead, CD44v may promote 
resistance to apoptosis by inducing survival signals. CD44 can signal through the PI3K-Akt 
and the MAPK pathway to support survival. For example, CD44v6 crosslinking was shown 
to protect from apoptosis in a thymoma cell line and this was accompanied by persisting 
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activation of MAPK signalling (Marhaba et al., 2005). In addition, in ASML cells CD44v6 is 
necessary for c-Met activation by mediating ligand binding through complex formation, 
resulting in phosphorylation of ERK (Orian-Rousseau et al., 2002). However, activation of 
MAPK-ERK signalling upon apoptotic triggers was not observed in ASML cells and does not 
seem to be influenced by CD44v expression, as wt and k.d. cells display comparable pERK 
levels. In addition, a MEK1/2 specific inhibitor failed to interfere with apoptosis resistance 
even at concentrations above MEK1/2 specificity inhibiting other members of the MAPK 
pathway, like ERK1 and MKK3/p38 as well. Instead, inhibition of PI3K enhanced 
susceptibility to apoptosis in wt and k.d. cells significantly. As inhibitors of PI3K-Akt are 
known to induce apoptosis at high concentrations on their own, the resistance to this 
treatment was tested without any additional apoptotic trigger.  Indeed, CD44vk.d. cells 
displayed reduced tolerance to high doses of PI3K and Akt inhibition compared to wt cells, 
demonstrating impaired PI3K-Akt signalling in CD44vk.d. cells. Accordingly, 
phosphorylation of Akt is reduced in the k.d. cells but not in wt cells upon ciplatin treatment 
and the anti-apoptotic molecule Bcl-2 is down-regulated only in the k.d. cells as well. In 
addition, antibody-crosslinking of surface CD44v induced phosphorylation of Akt in ASML 
cells. These findings clearly demonstrate that in CD44vk.d. cells one of the major survival 
pathways is impaired, and that PI3K-Akt signalling contributes, probably in conjunction with 
other triggers, to the high apoptosis resistance observed in ASMLwt cells. Although the 
rescue clones could not reverse this defect, an involvement of CD44 was confirmed by 
CD44v-mediated activation of survival signals through crosslinking.  
Activation of PI3K leads to phosphorylation and activation of Akt. Active Akt 
interferes with the apoptotic machinery by phosphorylating and inactivating the proapoptotic 
molecule BAD and by inhibiting transcription of pro- and inducing transcription of 
antiapoptotic molecules. In the active conformation BAD inhibits antiapoptotic members of 
the Bcl-2 family, which stabilize the mitochondrial membrane and support survival (Igney 
and Krammer, 2002). Because differences in pAkt levels become apparent after apoptotic 
triggering, PI3K signalling is not constitutively altered in CD44vk.d. cells, which is observed 
in many tumour cells through over-expression of PI3K subunits and Akt or lost expression or 
mutation of the PI3K antagonist PTEN (Igney and Krammer, 2002). Instead, impaired 
activation of PI3K by CD44 upon apoptotic triggering seems to account for the observed 
lowered tolerance of CD44vk.d. cells to cisplatin and γ-irradiation. Soluble HA oligomers, 
competing for HA binding to CD44 can inhibit anchorage-independent growth by 
suppressing PI3K-Akt (Ghatak et al., 2002). Ligation of CD44 could enhance resistance to 
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drug treatment by activating the protein tyrosine kinase FAK leading to PI3K association and 
activation of downstream targets of FAK, such as MAPKs (Fujita et al., 2002). Only 
interfering with PI3K signalling, but not with the MAPK pathway decreased resistance to 
apoptosis in this study as well. How CD44v induces PI3K activation remains to be explored 
in detail, but it seems likely, that CD44v associated protein kinases are involved. However, 
no associations with FAK or PI3K could be demonstrated by immunoprecipitations in ASML 
cells (data not shown). Another possibility might be an inhibiting activity of CD44v on PI3K 
antagonists, as soluble HA oligomers were demonstrated to be capable to stimulate the 
expression of the PI3K antagonist PTEN (Ghatak et al., 2002). An involvement of the 
described matrix production in apoptosis resistance seems likely as well. Activation of Akt 
upon crosslinking of CD44v argues for CD44 acting directly as receptor for matrix 
components, but, because crosslinking induces clustering as well, CD44v could also 
cooperate with other molecules, such as integrins to activate survival signalling in ASML 
cells. As β1 integrin was identified to mediate adhesion of ASML cells and ligation of β1 
integrins is known to support survival, both possibilities seem feasible and might even act 
synergistically.  
 
CD44v-mediated apoptosis resistance and adhesiveness as crucial contributions during the 
lymphatic spread of ASML cells 
The importance of apoptosis resistance for metastatic cancer cells and especially 
survival induced by the microenvironment is becoming more and more apparent. As 
reviewed by Mehlen and Puisieux (Mehlen and Piusieux, 2006), one way to explain the very 
rare incidence of metastatic outgrowth (Liotta et al., 1978; Varani et al., 1980) is to look at 
apoptosis acting as a multistep barrier to metastasis at three crucial steps. During the initial 
step of metastasis, cells detach from the underlying ECM and the actin cytoskeleton is 
disrupted leading to cell rounding.  These early events usually induce apoptotic processes 
called anoikis and amorphosis (Streuli et al., 1999, Martin et al., 2004) and cancer cells must 
become resistant to these apoptotic stimuli. The second step during which apoptosis can be 
induced is the process of intravasation and during residence in the circulation. Cell death may 
be induced by mechanical stress associated with entrance into the blood stream (Weiss et al., 
1993; Ziegler et al., 1998) or be mediated by the immune system, known as immune 
surveillance (Jakobisiak et al., 2003). Indeed, cancer cells display a high frequency of 
apoptosis when injected into the circulation, while over-expression of antiapoptotic 
molecules like Bcl-2 can increase the number of metastatic lesions at secondary sites (Wong 
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et al., 2001). Moreover, the tumour suppressor p53 was shown to facilitate experimental 
metastasis by promoting the survival of tumour cells in the circulation (Nikiforov et al., 
1996). Finally, after settlement cancer cells have to survive at the secondary site to form 
metastases, the third phase, when cancer cells display high frequency of apoptosis. Enhanced 
antiapoptotic signalling is supporting metastasis formation at this step as well (Wong et al., 
2001; Luzzi et al., 1998).  
 
Fig. 30: Apoptosis at three crucial steps during the metastatic spread of tumour cells 
a. Detachment from the primary tumour mass induces anoikis. b. Cell death in the circulation through 
immune surveillance or mechanical stress. c. Apoptosis after extravasation during micrometastasis 
formation at the secondary site. ECM extracellular matrix, NK natural killer cell. Adapted by 
permission from Macmillan Publishers Ltd: Nature Reviews Cancer (Mehlen and Puisieux., 2006).  
 
The observed CD44-mediated apoptosis resistance could protect ASML cells at 
different points in the metastatic process. ASML cells do not form tight cell-cell contacts 
under in vitro culture conditions and display only little local tumour growth in vivo. 
CD44vk.d. cells do not display reduced anchorage-independence. Thus, the initial step of 
dissemination from the primary tumour is probably not limiting for ASML metastasis 
formation. ASML cells spread exclusively via the lymphatics, therefore they do not need to 
invade blood vessels, and because lymphatics lack the tight inter-endothelial junctions of 
blood vessels (Alitalo and Carmeliet, 2002), intravasation should be less stressful for tumour 
cells and probably even allow small cell aggregates to enter. The growth in the draining 
lymph nodes was already reduced in CD44vk.d. cells, which argues for a growth and/or 
survival advantage in this environment, but the settlement in the lung seems to be most 
severely impaired in the CD44vk.d. clones. While cells from connective tissue tumours, like 
fibrosarcomas usually migrate individually, carcinomas were described to often migrate 
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collectively as small aggregates (Friedl and Wolf, 2003). It seems likely that ASML cells 
start to migrate as individual cells, enter the lymphatics and aggregate only once they reach 
the draining lymph node and are confronted with a HA-rich environment. This might be 
favouring growth and survival within the lymph node and the lymphatic vessels and probably 
facilitate further travel within the lymphatic system. The physiology of lymph nodes and the 
relatively low shear flow of lymphatic fluid was discussed in this context to favour the 
concentration of tumour cell aggregates in the lymph nodes, which then may support the 
growth of local metastases that could serve as ‘bridgeheads’ for further dissemination 
(Sleeman, 2000). In comparison, the metastatic progression in the lung is highly inefficient, 
which could be explained in this respect by the large capillary bed, leading to dispersal of 
individual tumour cells (Chambers et al., 2002). In addition, the lung seems to be harder to 
colonize than the lymph nodes also for ASML cells, as even the rapidly growing ‘v71-16’ 
clone exhibited impaired settlement in the lung. This could be due to the lack of CD44v-
mediated aggregation or adhesion or again to increased apoptosis. Aggregation may facilitate 
arrest in the capillary bed, which in turn would enable matrix deposition and subsequent firm 
adhesion. Adhesion to matrix possibly then promotes survival at the secondary site.  
Strong CD44-HA interaction can promote certain steps of the metastatic process, 
while weak CD44-HA interaction might favour others. For example, release of cells from the 
primary tumour is accompanied by reduced expression of CD44 in endometrial carcinoma 
(Fujita et al., 1994). CD44 was shown to mediate attachment of circulating cancer cells to the 
endothelial vessel wall through interaction with HA (De Grendele et al., 1996/1997). 
Moreover, survival during micrometastasis formation can be mediated by CD44-HA binding. 
This was shown in a mammary carcinoma cell line transfected with a soluble form of CD44, 
which competed for HA-binding. The cells were able to infiltrate lung tissue but underwent 
apoptosis thereafter and failed to form lung tumours (Yu et al., 1997). In addition, an 
influence of CD44 glycosylation on HA binding was demonstrated (Skelton et al., 1998; 
English et al., 1998). Because it is well known that glycosylation patterns are changed in 
cancers and that changes can increase with tumour progression (Alhadeff, 1989), it seems 
likely that changes in the HA binding ability of CD44 can by this means support the 
metastatic process at different steps. The loss of CD44v may therefore not only suppress 
metastasis formation by the inability to bind HA, but probably also because of the lost ability 
to modify this interaction in a dynamic manner. This could still be the case in the rescue 
clones and might be a reason for the limited ability of these cells to restore all observed 
phenotypes of the k.d. cells. For instance the untranslated regions (UTRs) of the CD44 
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transcript could be functionally involved, as the rescue cDNAs did not contain the 
endogenous UTRs. Recently the 3’ UTR of CD44 was described to be involved in 
translational control by stabilizing the transcript through bound IMPs, a family of 
ribonucleoproteins (RNPs). In addition, different CD44 variants exhibited differences in their 
3’UTR sequence and regulation by IMPs was isoform specific. Moreover, interfering with 
IMP function led to abrogation of invadopodia formation, which was attributed to the 
deregulation of CD44 (Vikesaa et al., 2006). IMPs are described to be involved in mRNA 
localization, with implications on coordinated spatio-temporal protein expression and 
overexpression of IMPs is implicated in cancer progression (Ioannidis et al, 2001; Tessier at 
al., 2004). This mechanism provides an additional level of complexity to CD44 regulation 
and it cannot be ruled out that similar mechanisms are responsible for the failure of the 
restored CD44 expression to rescue all observed phenotypes. The fact that the rescue clones 
restored the metastatic ability as well as the matrix production in part, but failed to restore 
apoptosis resistance is most easily explained by the lower overall CD44 expression level 
compared to the wt situation. Specifically, the initiation of signal transduction might depend 
on the expression level. It is also possible, that ASML cells require both isoforms, which 
were affected by the knock-down or that additional isoforms were targeted, but not restored.  
 
Future perspectives and conclusions 
Differential contributions of untranslated sequences during the course of metastasis 
formation seem very interesting with respect to CD44 regulation. Rescue constructs, carrying 
endogenous UTRs could be applied to the established k.d. cell system, to study influences on 
the metastatic growth in detail. As CD44 is reported to take part in the regulation of gene 
expression, it might be worthy to look for deregulated gene or protein expression in the k.d. 
cells, for example by microarray and CHIP analysis. With respect to the described matrix 
production, changes in the expression of matrix components or molecules involved in matrix 
remodelling, such as proteases could be addressed. In addition, the role of CD44v in matrix 
organization could be analysed by studying morphological differences by electron or 
fluorescence microscopy on deposited matrix material.  
As the rescue clones did not revert all CD44vk.d. phenotypes, e.g. the reduced 
expression of ‘complement component 3’, the CD44 specificity of these observations has to 
be critically judged. The only alternative way to control any phenotype arising by RNAi is to 
reproduce the same phenotype using a second construct. However, no stable clones could be 
established with the second functional construct. Due to a low transfection efficiency of 
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ASML cells, transient transfection is not practical either. However, the use of an inducible 
RNAi system could solve this problem, as generation of stable clones should be less 
problematic.  
This work demonstrates an essential contribution of CD44v to the metastatic capacity 
of ASML cells. However, considering the differences of AS and ASML cells, CD44v seems 
to support metastasis formation in different ways depending on the cellular background. AS 
cells adhere to and spread on different matrices, while ASML cells hardly adhere to any 
substrate except their own matrix. Therefore matrix generation might be a crucial feature of 
ASML cells but not for AS. Abrogation of HA binding had no influence on the metastatic 
capacity of AS cells transfected with CD44v (Sleeman et al., 1996) and hence, CD44v-
mediated aggregation in lymph nodes or the lung might not be limiting for AS cells, as these 
cells tend to build up tight cell-cell contacts anyhow. Still, the induction of agglomeration 
might be an essential contribution of CD44v on metastasis formation of ASML cells. In 
addition, upon transfection with CD44v, AS cells did not gain apoptosis resistance (data not 
shown). Accordingly, the multitude of differentially expressed genes between AS and ASML 
seems to influence the way CD44v contributes to metastatic progression of these cells. This 
strengthens the idea that actions of CD44v depend on the cellular background, which is not 
surprising given the heterogenous nature of CD44 functions and interactions.  
In summary, variant-specific down-regulation of CD44 in a highly metastatic 
pancreatic adenocarcinoma is accompanied by a markedly reduced metastatic capacity and 
settlement in the lung. Defects in proliferative or anchorage-independent growth were ruled 
out. Likewise, a change in the level of MMP2 and MMP9 secretion was not observed, which 
would have argued for differences in invasive capacities. On the other hand, several 
differences were examined and characterized, that could account for the observed metastatic 
defect. First, CD44vk.d. cells lost the ability to aggregate in a stromal surrounding due to 
their inability to crosslink surface CD44 through hyaluronic acid. Second, ASML cells 
secrete a highly adhesive matrix, containing HA, collagen and laminin, to which they adhere 
rapidly via β1 integrins and which might contribute to apoptosis resistance. CD44v are most 
likely involved in matrix production by assembly of a HA-rich scaffold and therefore 
CD44vk.d. cells display an impaired matrix generation. Finally, CD44vk.d. cells are clearly 
less resistant to apoptotic triggers, as demonstrated for drug resistance and γ-irradiation, 
which seems to be the cause of impaired PI3K-Akt signalling due to the loss of CD44v-
mediated activation.  
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These results support the idea of CD44 as a molecule with multiple features that, due 
to its compositional and functional heterogeneity influences tumour progression and 
metastasis formation at several different steps. Even in the studied cell system, which reflects 
only the advanced steps of tumour progression, CD44v contributes to the process of 
metastasis formation in several ways: as a cell-cell adhesion molecule, as organizer of 
extracellular matrix components and as signalling molecule influencing survival. Importantly, 
all the described mechanisms are based on complex interactions of CD44v on the tumour cell 
with its surrounding in diverse ways. This underlines the importance of communication 
between cancer cells and their microenvironment for the metastatic cascade, which is a major 
subject of recent investigation and possesses growing importance for future therapeutic 
strategies.   
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4.  Materials and Methods 
4.1  Materials 
4.1.1  Chemicals 
 
Agar  Fluka, Buchs, Schweiz 
Agarose Sigma, Seelze 
3-Amino-9-ethyl-carbazol (AEC) Sigma, Seelze 
Ammoniumpersulfate (APS) Sigma, Seelze 
Ampicillinsulfate  Sigma, Seelze 
Biotin-X-NHS Calbiochem, Darmstadt 
Brij98 Fluka, Buchs, Schweiz 
Brilliant Blue G-Colloidal Concentrate Sigma, Seelze 
Bromphenolblue Merck, Darmstadt 
Cisplatin (cis-diammineplatimun(II)dichloride) Sigma, Seelze 
Ethidiumbromide Merck, Darmstadt 
Ethylendiamintetraessigsäure (EDTA) Sigma, Seelze 
Fetal calf serum (FCS)  Sigma, Seelze 
Formaldehyde 37% Merck, Darmstadt 
Glucose Merck, Darmstadt 
Glutamine Life Technologies, Karlsruhe 
Glycerine Roth, Karlsruhe 
Glycine Roth, Karlsruhe 
Yeast extract  Gibco BRL, Eggenstein 
HEPES  Sigma, Seelze 
Hyaluronic acid (from rooster comb) Sigma, Seelze 
Kanamycinsulfate Calbiochem, Darmstadt 
Lubrol WX (17A17)  Serva, Heidelberg 
Milk powder Roth, Karlsruhe 
Mayer’s Hämalaun AppliChem, Darmstadt 
β -Mercaptoethanol  Sigma, Seelze 
Mowiol (4-88)  Calbiochem, Darmstadt 
Natriumorthovanadat  Sigma, Seelze 
Paraformaldehyde  Sigma, Seelze 
Penicillin Sigma, Seelze 
Pepton 140  Gibco BRL, Eggenstein 
Phenylmethylsulfonylfluorid (PMSF) Sigma, Seelze 
Protease Inhibitor Cocktail  Roche Diagnostics, Mannheim 
Protein G Sepharose 4 Fast Flow Amersham Pharmacia, Freiburg 
Rotiphorese Gel 30  (Acrylamid-Mix) Roth, Karlsruhe 
Sepharose CL-6B Amersham Biosc., Freiburg 
Sepharose Superdex 200 Amersham Biosc., Freiburg 
Streptomycinsulfate Sigma, Seelze 
TEMED Sigma, Seelze 
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3H-Thymidine  Amersham Biosc., Freiburg 
Triton X-100  Sigma, Seelze 
Trypsin  Sigma, Seelze 
Tween 20  Serva, Heidelberg 
 
All other chemicals, not listed were analytical grade and purchased from Sigma (Seelze), 
Calbiochem (Darmstadt), Serva (Heidelberg) or Applichem (Darmstadt).  
 
4.1.2  Enzymes 
resctriction enzymes MBI Fermentas, St. Leon Rot 
Taq-polymerase MBI Fermentas, St. Leon Rot 
PWO-polymerase Promega, Mannheim 
T4-Ligase Promega, Mannheim 
T4-Polynucleotidkinase (T4-PNK) Promega, Mannheim 
Klenow fragment Promega, Mannheim 
ImProm II reverse transcriptase Promega, Mannheim 
calf intestinal alkaline phosphatase (CIAP) Promega, Mannheim 
hyaluronidase type IV-S from bovine testis Sigma, Seelze 
collagenase, type 2 PAA, Coelbe 
 
 
4.1.3  Chemical inhibitors 
LY294002(PI3-K-inhibitor) Calbiochem, Darmstadt 
Akt II inhibitor Calbiochem, Darmstadt 
MEK1/2-inhibitor Calbiochem, Darmstadt 
 
4.1.4  Nucleotide and protein standards 
100bp Gene Ruler MBI Fermentas, St. Leon Rot 
1 kb Gene Ruler MBI Fermentas, St. Leon Rot 
Prestained Protein ladder MBI Fermentas, St. Leon Rot 
 
4.1.5  Kits 
Qiaprep Spin miniprep kit QIAGEN, Hilden 
Qiaquick Gel Extraction Kit QIAGEN, Hilden 
Qiaquick midi prep kit QIAGEN, Hilden 
ECL Western Blotting Detection Reagents Amersham Biosc., Freiburg 
Vectastain ABC kit Vector Laboratories, Burlingame, USA 
TRI Reagent Sigma, Seelze 
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4.1.6  Vectors 
vector description company 
pSuper.gfp/neo eukaryotic expression vector for 
RNAi 
Oligoengine, Seattle, 
USA 
pcDNA3.1(+)Neo eukaryotic expression vector Invitrogen, Karlsruhe 
pcDNA3.1(+)Hygro eukaryotic expression vector Invitrogen, Karlsruhe 
 
4.1.7  Primers and oligos 
Oligonucleotides were purchased from Operon Biotechnologies (Koeln) 
 
oligo sequence 
v6RNAi-sense 5’−TCGAGGCACAACAGAAGAAGCAGCTACCCAGAACTTCCTGT
CATTCTGGGTAGCTGCTTCTTCTGTTGTGCTTTTT−3’ 
v6RNAi-
antisense 
5’−CTAGAAAAAGCACAACAGAAGAAGCAGCTACCCAGAATGA
CAGGAAGTTCTGGGTAGCTGCTTCTTCTGTTGTGCC−3’ 
v7RNAi-sense 5’−TCGAGAGAATGACAACACAGAGTCAAGAGGATGCTTCCTGT
CACATCCTCTTGACTCTGTGTTGTCATTCTTTTTT−3’ 
v7RNAi-
antisense 
5’−CTAGAAAAAAGAATGACAACACAGAGTCAAGAGGATGTGA
CAGGAAGCATCCTCTTGACTCTGTGTTGTCATTCTC−3’ 
v6/v7RNAi-
sense 
5’−TCGAGCAACTGCCTCAGCCCACAACTTCAAGAGAGTTGTGG
GCTGAGGCAGTTGTTTTT−3’ 
v6/v7RNAi-
antisense 
5’−CTAGAAAAACAACTGCCTCAGCCCACAACTCTCTTGAAGTT
GTGGGCTGAGGCAGTTGC−3’ 
T7-BglII-R 5’−GAGCTAGATCTAATACGACTCACTATAGGG−3’ 
EcoRI-CD44-F 5’−GCAGTGAATTCCCACCATGGACAAGGTTTGGTGGCAC−3’ 
CD44-XhoI-
Stop-R 
5’−CGACGCTCGAGGCACTACACCCCAATCTTC−3’ 
v7resc-F 5’−TACTCAGTCTCAAGAGGATG−3’ 
v6/v7resc-F 5’-CAACTGCCAGCGCGCACAACAAC−3’ 
CXCR4-F 5’−CCCTCCTCCTGACTATCCCT−3’ 
CXCR4-R 5’−TGACTCTGTGGAGACGGAAGA−3’ 
CCR7-F 5’−GGCGAGAACACCACCGTGGAC−3’ 
CCR7-R 5’−TTCTGGAGGCCGCTGTAGA−3’ 
SDF1-F 5’−GCCAAGGTCGTCGCTGTGCT−3’ 
SDF1-R 5’−TTGGATCCACTTTAATTTCGG−3’ 
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4.1.8  cDNAs and constructs 
 
CD44v4-v7 cDNA and CD44v6/v7 cDNA (Gunthert et al., 1991; Rudy et al., 1993) were 
used as template for PCR amplification. All constructs were verified by sequencing.  
 
construct vector insert cloning sites 
pSuper-v6 pSuper.gfp/neo CD44v6RNAi-hairpin BglII-HindIII 
pSuper-v7 pSuper.gfp/neo CD44v7RNAi-hairpin BglII-HindIII 
pSuper-v6/v7 pSuper.gfp/neo CD44v6/7RNAi-hairpin BglII-HindIII 
meta1-rescv7 pcDNA3.1Hygro CD44v4-v7-rescuev7-cDNA EcoRI-XhoI 
meta2-rescv7 pcDNA3.1Hygro CD44v6/v7-rescuev7-cDNA EcoRI-XhoI 
meta1-rescv6/v7 pcDNA3.1Hygro CD44v4-v7-rescuev6/v7-cDNA EcoRI-XhoI 
meta2-rescv6/v7 pcDNA3.1Hygro CD44v6/v7-rescuev6/v7-cDNA EcoRI-XhoI 
CD44meta1 pcDNA3.1Hygro CD44v4-v7-cDNA EcoRI-XhoI 
CD44meta2 pcDNA3.1Hygro CD44v6/v7-cDNA EcoRI-XhoI 
 
4.1.9  Antibodies 
4.1.9.1 Primary antibodies 
antibody (clone) application company/reference 
mouse anti rat CD44pan (Ox50) FACS, IP, blocking exp. Paterson et al. 1987 
mouse anti ratCD44v6 (A2.6) FACS, IP, blocking exp., 
immunohistology, WB,  
Matzku et al. 1989 
mouse anti rat EpCAM (D5.7) FACS, IP, WB Wurfel et al., 1999 
mouse anti rat D6.1A (D6.1) FACS, IP, WB Claas et al., 1998 
mouse anti rat C4.4A (C4.4) FACS, immunohistology Rosel et al., 1998 
mouse anti rat transferrin 
receptor (Ox26) 
FACS, IP, WB European Collection of 
Animal Cell Culture  
mouse anti rat α3β1  integrin 
(Ralph3.1) 
FACS, IP, blocking exp. Developmental Studies, 
Hybvridoma Bank  
mouse anti rat α6β4 integrin 
(B5.5) 
FACS, blocking exp. Herlevsen et al., 2003 
mouse anti rat β1 integrin 
(Ha2/5) 
FACS, IP, blocking exp. BD Biosciences, 
Heidelberg 
rabbit anti human α3 integrin 
(polyclon.#AB1920) 
WB Chemicon, Temecula, 
Canada 
hamster anti rat α2 integrin 
(Ha1/29) 
FACS, blocking exp. BD Biosciences, 
Heidelberg 
mouse anti rat α6β1 integrin 
(MAB1410) 
FACS Chemicon, Temecula, 
Canada 
mouse anti rat α4 integrin 
(MRα4-1) 
FACS BD Biosciences, 
Heidelberg 
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hamster anti rat α1 integrin 
(Ha31/8) 
FACS BD Biosciences, 
Heidelberg 
hamster anti mouse α5 integrin 
(HMα5-1) 
FACS BD Biosciences, 
Heidelberg 
mouse anti rat β2 integrin 
(WT.3) 
FACS BD Biosciences, 
Heidelberg 
mouse anti rat β3 integrin (F11) FACS BD Biosciences, 
Heidelberg 
mouse anti human ERK (16) WB BD Biosciences, 
Heidelberg 
mouse anti human pERK1/2 
(20A) 
WB BD Biosciences, 
Heidelberg 
mouse anti human Akt (2) WB BD Biosciences, 
Heidelberg 
mouse anti human pAkt 
(104A282) 
WB BD Biosciences, 
Heidelberg 
mouse anti human Bcl-2(7) WB BD Biosciences, 
Heidelberg 
rabbit anti human laminin 
(polyclon. #600-401-116-05) 
WB, blocking exp. Rockland, Gilbertsville, 
USA 
goat anti rat complement C3 
(polyclon.#5571304564) 
WB MP Biomedicals, Aurora, 
Ohio, USA 
 
4.1.9.2 Secondary antibodies/ reagents 
antibody application company 
anti mouse-IgG-TxRed immunofluorescence dianova, Hamburg 
anti mouse-IgG-biotin immunohistology dianova, Hamburg 
anti mouse-IgG-HRP WB Rockland, Gilbertsville, USA 
anti goat-IgG-HRP WB Rockland, Gilbertsville, USA 
anti rabbit-IgG-HRP WB Rockland, Gilbertsville, USA 
Extravidin-Peroxidase WB  Sigma, Seelze 
anti mouse-IgG-PE FACS dianova, Hamburg 
anti mouse-IgG-APC FACS BD Biosciences, Heidelberg 
anti mouse-IgG-FITC FACS dianova, Hamburg 
anti rabbit-IgG-PE FACS dianova, Hamburg 
anti hamster-IgM-FITC FACS dianova, Hamburg 
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4.1.10 Cell lines 
Cell line source reference 
BSp73ASML Rattus norvegicus, pancreas 
adenocarcinoma 
Matzku et al., 1983 
BSp73AS Rattus norvegicus, pancreas 
adenocarcinoma 
Matzku et al., 1983 
BSp73AS-14 Rattus norvegicus, pancreas 
adenocarcinoma BSp73AS, transfected 
with cDNA for CD44v4-v7 
Gunthert et al., 1991 
HEK 293T Homo sapiens, renal cell carcinoma Graham et al., 1977 
Fibroblasts Rattus norvegicus, immortalized lung 
fibroblasts 
Weth, 2000 
ST-A4 Rattus norvegicus, immortalized 
lymph node stromal cell 
LeBedis et al., 2002 
ST-B12 Rattus norvegicus, immortalized 
lymph node stromal cell 
LeBedis et al., 2002 
 
 
4.1.11 Animals 
BDX rats were bred at the animal facilities of the German Cancer Research Center (DKFZ), 
kept under pathogen free conditions and fed with sterilized food and water.  
 
 
4.2  Methods 
4.2.1  Molecular biology 
4.2.1.1 Bacteria 
For all bacterial work DH5α were used. DH5α were cultured in liquid Luria Bertani 
(LB) medium (10g peptone, 5g yeast extract, 10g NaCl per l) or on plates containing 1% 
(w/v) bacto agar and either 60µg/ml ampicillin or 50µg/ml kanamycin for selection. 
Transformations were carried out with an ‘EasyJect’ electroporator (Eurogentec, Seraing, 
Belgium) using standard protocols for electro-transformation.  
 
DH5α genotype:  Φ80dlacZΔM15, recA1, endA1, gyrA96, thi-1, hsdR17(rK-, mK+), supE44,  
relA1, deoR, Δ(lacZYA-argF)U169; 
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4.2.1.2 Plasmid preparation 
All plasmid preparations were carried out using either the ‘QIAprep spin Miniprep 
kit’ or ‘plasmid midi prep kit’ (both QIAGEN, Hilden) according to manufacturer’s 
instructions.  
 
4.2.1.3 RNAinterference (RNAi) construct design and cloning 
In order to create stable CD44 knock-down clones the pSuper plasmid based RNAi 
system (oligoengine, Seattle, USA) was used. The pSuper plamids facilitate expression of 
‘small hairpin RNAs’ (shRNAs) under the control of the human RNA polymerase III 
promoter H1, which were shown to enter the endogenous RNAi pathway and induce 
degradation of the target mRNA. A GFP reporter and a neomycin resistance are included in 
the vector for detection and selection of transfected cells.  
 
Fig. 31: pSuper.gfp/neo inserts and predicted haipin structure  
A. ds inserts for cloning into pSuper.gfp/neo. The target sequences lie within exon v6, v7 or span the 
border of exon v6/v7. Due to the self-complementary sequence, transcripts fold into a 
hairpinstructure, which is processed by the endogenous RNAi machinery to a functional siRNA 
leading to target mRNA degradation. B. Predicted hairpin structure for construct ‘v7’.  
 
The target sites were chosen on the premise to target the two most abundant CD44 
variant isoforms, expressed by ASML, which are v4-v7(meta1) and v6/v7(meta2). Target 
sites for constructs ‘v6’ and ‘v7’ were chosen randomly, except that stretches of more than 3 
A-residues were avoided. Homologies to other genes were excluded by ‘BLAST’ search. For 
A               B 
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the ‘v6/v7’ construct, which spans the border of the v6-v7 exons, the RNAi target site 
validation program ‘Sfold’ was used, which is provided on the homepage of Wadsworth 
Center-NYS, Department Of Health (http://sfold.wadsworth.org; Ding et al., 2004; Ding and 
Lawrence, 2001/2003) and includes several parameters like internal stability of the siRNA-
dublex and target site accessibility. The constructs consist of a self complementary sequence 
stretch comprising the 21-28 bp target sequence and the corresponding reverse complement, 
separated by a 10 bp loop and followed by a stretch of 5 T-residues leading to termination of 
transcription. Sense and antisense oligos were designed to elicit sticky ends upon annealing. 
200pmol of each ss oligo were diluted in ligation buffer (Promega, Mannheim), boiled for 
2min and slowly cooled down to room temperature to ensure proper annealing. Because 
oligos were initially designed for XhoI-XbaI cloning, the ds inserts were partially filled up 
and ligated into the, as well partially filled up, Bgl II/Hind III sites of the pSuper.gfp/neo 
plasmid. Positive clones were verified by sequencing and used for transfections.  
 
4.2.1.4 PCR-based mutagenesis for rescue constructs 
In order to be able to control specificity of any phenotype arising in the knock-down 
cells, ‘rescue’ clones were established, in which expression of one of the dominant variants 
was restored. This was achieved by transfection of cDNAs for either CD44v4-v7 or 
CD44v6/v7, protected from degradation by four silent point mutations (highlighted in red) in 
the v7 target sequence, which were introduced by PCR.  
 
v7 target site:  AGAATGACAACACAGAGTCAAGAGGATG   
v7 rescue site:  AGAATGACTACTCAGTCTCAAGAGGATG  
 
The amplificates were cloned into pCDNA3.1Hygro (Invitrogen, Karlsruhe) and 
positive clones were varified by sequencing. One of the stable knock-down clones, 
ASMLv71-14 was used for transfections with the ‘rescue’ constructs.  
 
4.1.2.5 RNA-isolation and reverse transcription-PCR (RT-PCR) 
 RNA preparations were carried out with ‘TRI Reagent’ (Sigma, Seelze). About 5x106 
cells were lysed directly into 1ml of TRI Reagent by scraping. After addition of 0.2ml 
chloroform and centrifugation (12000g, 15min, 4°C) the aqueous phase was transferred and 
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RNA was precipitated with isopropanol. After centrifugation the pellet was washed with 
ethanol, air-dried and resuspended in DEPC treated H2Od. Integrity of the isolated RNA was 
controlled by gelelecrophoresis.  
cDNA was generated using the ‘ImProm II’ system (Promega, Mannheim) with oligo 
(dT) primers following the manufacturer’s instructions. 2µl of the reverse transcription 
reaction was used as template for the PCR.  
 
4.2.2  Cell biology 
4.2.2.1 Cell culture 
Eukaryotic cells were kept in RPMI 1640-medium, containing 10% heat inactivated 
fetal calf serum (FCS), 100U/ml penicillin, 100µg/ml streptomycin and cultured at 37°C, 
95% humidity, 5% CO2. For passaging, cells were trypsinized with 0.25% trypsin (w/v)/5mM 
EDTA in PBS (137mM NaCl, 8,1mM Na2HPO4, 2,7mM KCl, 1,5mM KH2PO4, pH 7.4). 
 
4.2.2.2 Cryo-conservation of eukaryotic cells 
1x107 cells were trypsinized, washed once with fresh medium and resuspended in ice-
cold FCS/10% DMSO. Cells were kept over night at -80°C and transferred to liquid nitrogen.  
 
4.2.2.3 Transfection of eukaryotic cells 
ASML cells were seeded the day before transfection to 70% confluency. Transfection 
was carried out with the ‘ExGene 500’ reagent (MBI Fermentas, St.Leon Rot) following the 
instructions of the manufacturer. HEK293T cells were transfected with ‘PolyFect 
Transfection reagent’ (QIAGEN, Hilden) at 50% confluency according to the manufacturer’s 
instructions.  
 
4.2.2.4 Recloning of transfected cells by limiting dilution 
Transfected cells were selected for drug resistance and checked by FACS for 
expression of the transgene. Limiting dilutions of 1 or 5 cells per well were carried out in 24-
well plates. Cells were grown in the presence of 1x106 freshly prepared rat thymocytes as 
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growth support. Clones were checked by FACS and used for a second round of dilution to 
ensure clonality.  
 
4.2.2.5 Collection of conditioned cell culture supernatant  
90% confluent cells were grown in serum free medium for 24h, the supernatant was 
harvested and centrifuged to remove cells (300g, 10min). Cell free supernatant was filtered 
through a 0.2µm filter and either coated to 24-well plates for adhesion assays, or concentrated 
through a ‘Vivaspin 6 column’ (50.000 MWCO) (Sartorius, Goettingen) and used for SDS-
PAGE or gel filtration.  
Deposited matrix was prepared by cultivating confluent cells for 24 hours and 
removing cells by EDTA treatment (5mM in PBS, pH8.0), followed by intensive washing 
with PBS.  
 
4.2.2.6 Coating of plastic surfaces 
Proteins bind under alkaline conditions to plastic surfaces. 50mM Tris (pH 9.5) was 
used as a binding buffer for matrix components, which were coated at a concentration of 
10µg/ml. Collagens were pre-incubated at 37°C for 4h prior to coating. Hyaluronic acid was 
coated at very high concentrations (1mg/ml) under neutral pH in PBS. Conditioned cell 
culture supernatant was coated at pH 7.4. All coatings were carried out over night at 4°C, 
wells were washed once with PBS, followed by blocking with BSA (3mg/ml in PBS) for 2h 
at RT and three washes with PBS. Coated plates were used for adhesion assays.  
Where indicated, conditioned cell culture supernatant was treated with hyaluronidase 
(Sigma, Seelze) or collagenase (Sigma, Seelze) for 4 h at 37°C prior to or after coating. Heat 
inactivated enzymes were used as controls.  
 
4.2.2.7 Adhesion assay 
Cells were trypsinized and recovered for 1-2h in RPMI/10% FCS. Adhesion assays 
were carried out in 24-well plates. Cells were washed with PBS, counted and 1x106 cells 
were resuspended in serum free medium or PBS with or without additives. Cells were seeded 
and incubated at 37°C for 15min. Adherent cells were stained with crystal violet (see section 
4.2.2.14). 
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4.2.2.8 Agglomeration assay 
Cells were trypsinized and recovered for 1-2h and resuspended in conditioned cell 
culture supernatant of different origin. Where indicated, cell culture supernatant was treated 
with hyaluronidase (1mg/ml) at 37°C for 2 or 5h before use, or cells were seeded in RPMI 
medium, supplemented with 1mg/ml hyaluronic acid. Agglomeration was monitored with a 
Leica ‘DM-IL’ inverse microscope (Leica, Solms) and documented with a SPOT CCD 
camera using the SPOT 2.1.2 software.  
 
4.2.2.9 Proliferation assay 
5x104 cells were seeded in 96-well plates in RPMI supplemented with 10% or 0.5% 
FCS. 3H-thymidin was added for 24h at different time points. Cells were harvested and H3 
incorporation was counted in a liquid scintillation counter. Alternatively 5x104 cells were 
seeded as before and quantified by crystal violet staining after different time intervals (see 
section 4.2.2.14).  
 
4.2.2.10 Soft agar assay 
Tumour cells were suspended in RPMI/0.5% agar and either 100 or 1000 cells were 
seeded on a pre-poured RPMI/3% agar layer in the presence of 10% FCS. Colonies were 
counted after 4 weeks.  
 
4.2.2.11 Drug treatment 
1x105 cells per well were seeded in 96-well plates and grown overnight. Serial 
dilutions of a 50µg/ml starting concentration of cisplatin in RPMI medium were carried out 
in 1:2 steps.  For chemical inhibitors starting concentrations were 100mM for the MEK1/2 
and Akt II inhibitor and 200mM for the PI3K specific inhibitor LY294002 (Calbiochem, 
Darmstadt). Cells were treated for 3 days and surviving cells were stained either by MTT 
staining or crystal violet staining.  
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4.2.2.12 γ-irradiation of adherent cells 
1x106 cells were seeded in 35mm petridishes, grown for 15, 24 or 48h, fresh medium 
was added and monolayers were subjected to different doses of γ-irradiation in a 
‘GAMMACELL 1000D’ unit (AECL, Ontario, Canada). Survival was monitored by MTT 
staining after 72h. Where indicated, chemical inhibitors were added 30min prior to 
irradiation.  
 
4.2.2.13 MTT staining of respiratory active cells 
A 5mg/ml stock solution of MTT in PBS was diluted 1:10 directly in the growth 
medium of the cells and incubated for 30-40min at 37°C. Non-adherent cells were 
precipitated by centrifugation, the supernatant was aspirated and cells were resuspended in 
DMSO and measured at 550nm in an ELISA reader.  
 
4.2.2.14 Crystal violet staining of adherent cells 
Adherent cells were washed and fixed with 4% formalin in PBS for 4min at RT. The 
solution was changed to 1% crystal violet (in 10% EtOH) and incubated for 4min at RT. The 
plates were washed extensively with H2Od, dried and cells were resuspended in 10% acetic 
acid. Absorbance was measured at 595nm in an ELISA reader.  
 
4.2.2.15 FACS analysis 
For FACS staining, cells were trypsinized and recovered in complete medium for 1-
2h. Staining was performed in U-shaped 96-well plates with 106 cells per well. Incubation 
with primary and secondary antibodies in PBS was carried out at 4°C for 30min in the dark. 
After each step cells were washed three times with PBS by centrifugation at 300g for 4min. 
FACS analysis was performed using a ‘FACSCalibur’ (Becton Dickinson, Heidelberg) and 
analyzed with the ‘CellQuest Pro’ software.  
 
4.2.2.16 Immunofluorescence staining of cells grown on coverslips 
Cells were grown on coverslips for 1-2 days. Adherent cells were washed three times 
with PBS and fixed with 4% paraformaldehyde (PFA) in PBS for 25min on ice, followed by 
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three washes with PBS/200mM glycine and three washes with PBG (PBS, 0.2% (v/v) 
gelatine, 0.5% (w/v) BSA). Primary antibody incubation was carried out for 1h at 4°C in 
PBG, followed by three washes with PBG. After incubation with Texas-Red conjugated 
secondary antibody for another hour at 4°C and three more washes with PBG, cells were 
rinsed with H2Od, air-dried and mounted in Elvanol (20% (w/v) Mowiol in 2/3 PBS, pH 8.0 
and 1/3 glycerine). Fluorescence microscopy was done using a Leica DMRBE microscope, 
equipped with a SPOT CCD camera using the SPOT 2.1.2 software for documentation.  
 
4.2.2.17 Cryo-sectioning of tumour tissue 
Tissues were embedded in frozen section medium ‘Neg-50’ (Richard-Allan Scientific, 
Kalamazoo, USA) and frozen in liquid nitrogen. Cryo-sectioning was carried out with a 
Reichert Jung ‘2800-FRIGOCUT E’ to sections of 5µm thickness and transferred to 
chromalaune-gelatine coated glass slides for staining.  
 
4.2.2.18 Immunohistological staining of cryo-sections 
Sections were blocked with PBS/2% FCS for 30min, fixed with acetone/methanol 
(1:1) for 4min and washed with PBS. All incubation steps were carried out at 37°C in a 
humidity chamber. Sections were stained with primary antibodies or mouse IgG for 1h, after 
washing and incubation with biotinylated secondary antibody, detection was carried out using 
the ‘Vectastain ABC kit’ according to the manufacturer’s instructions. Briefly, Vectastain 
AB-complex (containing avidin and biotinylated-peroxidase) was added for 30min, followed 
by incubation for 5-20min at RT with freshly prepared AEC mix [AEC-solution-1 (2.1ml 
acetic acid (0.1M), 7.9ml sodiumacetate (0.1M)) + AEC-solution-2 (4mg 3-amino-9-ethyl-
carbazole (AEC) in dimethylformamide (DMF)) + 5µl H2O2 (30%)]. After washing with 
PBS, sections were counterstained with Mayer’s Haemalaun and mounted in ‘Kaisers 
glycerine-gelatine’. Microscopy was done using a Leica DMRBE microscope, equipped with 
a SPOT CCD camera using the SPOT 2.1.2 software for documentation.  
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4.2.3  Animal experiments 
4.2.3.1 In vivo metastasis assay 
1x106 tumour cells were suspended in PBS and injected into the footpad of 10-14 
week old female BDX rats. Animals were sacrificed on day 50 in experiment 1 and on day 60 
in experiment 2. Rats were dissected and diameters of primary and lymph node tumours were 
measured. Lungs were photographed and weighed. Samples of infiltrated tissues were 
embedded for cryo-sectioning and immunohistology or recultivated. For recultivation, 
tumour tissue was meshed through a sterile gauze and seeded in RPMI-medium.  
 
 
4.2.4  Protein biochemistry 
4.2.4.1 Surface biotinylation of molecules 
Adherent cells were washed twice in PBS and incubated 30min at RT with 100-
500µg/ml Biotin-X-NHS (Calbiochem, Darmstadt) in 25mM HEPES/150mM NaCl/5mM 
MgCl2 on a shaking platform. Cells were washed three times with ice-cold PBS/200mM 
glycine and suspended in lysis buffer by scraping.   
 
4.2.4.2 Immunoprecipitation (IP) 
6x gel loading buffer:  300mM Tris pH6.8, 12% (w/v) SDS, 0.6% (w/v), bromophenolblue, 
20% (v/v) glycerine 
 
Lysis of cells was performed on ice or at 4°C and lysates were kept cold during the 
whole procedure. Cells were washed twice with PBS and scraped into ice-cold lysis buffer 
(25mM HEPES, 150mM NaCl, 5mM MgCl2, 2mM PMSF, 1x proteinase inhibitor mix 
(Roche, Mannheim), 1% (v/v) detergent). Lysis was performed on a rotating platform for 1h. 
Unsolubilized material and cell nuclei were pelleted by centrifugation (15min, 15000g) and 
the cleared lysate was used for IP. Either 5µg purified antibody or 200µl hybridoma 
supernatant was used per 1ml cell lysate. Antibody binding was carried out for 1h on a 
rotating platform. For precipitations, 0.1 volumes protein G Sepharose was added to the 
antibody complexes and samples were rotated for another hour. Complexes were washed 4 
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times with lysis buffer. After the last washing step all liquid was removed through a 35g-
needle attached to a vacuum line to ensure minimal background. Complexes were 
resuspended in gel loading buffer and boiled for 5min at 95°C. Sepharose beads were 
pelleted by short centrifugation and the supernatant was subjecetd to SDS-PAGE. For Re-IPs, 
the sepharose complexes were resuspended in lysis buffer containing a detergent of higher 
stringency (usually TX-100) and extracted for 1h at 37°C on a shaker. After removal of the 
sepharose, the supernatant containing the extracted antigens was subjected to another round 
of IP as described above.  
 
4.2.4.3 Lysis of intact cells for SDS-PAGE 
For western blotting of cell lysates from complete cells, cells were washed twice with 
PBS and scraped directly into gel loading buffer. Cell lysates were sonicated (5 impulses, 
5sec each). Lysates were boiled for 4min and used for western blot analysis.  
 
4.2.4.4 SDS-polyacrylamide gel electrophoreses (SDS-PAGE) 
For electrophoretic separation of protein samples the ‘Mini-Protean II’ system from 
Biorad (Munich) was used for discontinuous SDS-PAGE. 5ml of separating gel (375mM Tris 
pH 8.8, 0.1% (w/v) SDS, 6-12% acrylamid-bisacrylamid, 0.1% (v/v) TEMED, 0.1% (w/v) 
ammoniumpersulphate) were overlaid with 2ml of stacking gel (375mM Tris pH 6.8, 0.1% 
(w/v) SDS, 5% acrylamid-bisacrylamid, 0.1% (v/v) TEMED, 0.1% (w/v) ammonium-
persulphate). After complete polymerization, gels were loaded and run in gel running buffer 
(25mM Tris, 192mM glycine, 0.1% (w/v) SDS) at a constant voltage of 200V. Gels were 
either stained with Colloidal Coomassie or silver or subjected to western blot analysis.  
 
4.2.4.5 Western blotting (modified after Towbin et al., 1979) 
After SDS-PAGE, protein gels were equilibrated for 10min in transfer buffer (25mM 
Tris, 192mM glycine, 0.02% (w/v) SDS, 20% (v/v) methanol). Nitrocellulose membranes 
(Amersham, Braunschweig) and 3MM whatman paper were equilibrated as well. For protein 
transfer, the gel was placed on whatman paper, followed by nitrocellulose and another 
whatman paper. The wet transfer was carried out in transfer buffer at a constant voltage of 
30V over night at 4°C.  
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After transfer had been completed, the membranes were blocked for 1h at room 
temperature with 5% (w/v) fat free milk in PBST (PBS/0.1% (v/v) TWEEN 20) or, for 
detection with phosphospecific-antibodies, with 5% (w/v) BSA in TBST (TBS/0.1% (v/v) 
TWEEN 20). Antibody incubations were carried out for 1h at RT with hybridoma 
supernatant or purified antibody in PBST or TBST, respectively. Membranes were washed 
three times for 5min in PBST or TBST and incubated with secondary antibody conjugated to 
horseradish peroxidase (HRP) (diluted 1:5000 in PBST or TBST) for 1 h at RT, followed by 
additional three washing steps.  
Biotinylated proteins were detected with ExtrAvidin-peroxidase (Sigma, Seelze). 
Detection was done by chemiluminescence using the ‘ECL Western blotting detection 
reagents’ and ‘ECL radiography films’ (both Amersham, Braunschweig).  
 
4.2.4.6 Colloidal Coomassie staining of protein gels 
After electrophoretic separation, proteins were fixed for 1h in 7% acetic acid/40% 
(v/v) methanol. Gels were stained over night in staining solution (4 volumes Colloidal 
Coomassie staining solution (Sigma, Seelze) + 1 volume methanol). Gels were destained for 
30s in 10% acetic acid/25% (v/v) methanol and kept in 25% (v/v) methanol.  
 
4.2.4.7 Silver staining of protein gels  
After separation of proteins by SDS-PAGE, gels were fixed over night in 30% 
ethanol/10% acetic acid and sensitized for 45min (in 0.3% potassium tetrathionate, 0.5M 
potassium acetate, 30% ethanol), followed by 6 washes a 10min with H2Od. Gels were 
stained with 0.2% silver nitrate for 1-2 h, rinsed with H2Od and developed for up to 40min in 
developer (3% potassium carbonate, 31µl Na2S2O3-5H2O (10%), 75µl formalin (37%) per 
250ml). The reaction was stopped by adding 330mM TRIS/2% acetic acid and gels were kept 
in H2Od.  
 
4.2.4.8 Gelatine zymography for detection of MMP activity 
Conditioned cell culture supernatant was collected as described and concentrated 10 
times through a ‘Vivaspin’ column (50.000 MWCO) (Sartorius, Goettingen). The supernatant 
was mixed with Laemmli buffer, incubated for 15min at 37°C and subjected to SDS-PAGE 
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in an 8% acrylamide gel containing 1mg/ml gelatine as substrate. After electrophoresis the 
gel was incubated three times for 40min in 2.5% (v/v) TX-100, washed in developing 
solution (50mM Tris pH 7.4, 10mM CaCl2, 150mM NaCl2) and incubated for 24h in 
developing solution at 37°C and subsequently subjected to Coomassie staining.  
 
4.2.4.9 Gel-filtration 
Superdex 200/CL6B sepharose beads were washed in PBS/0.1% NaN3, degased and 
packed into a column of 1.5cm diameter and 60cm length. The column material was 
equilibrated with PBS/0.1% NaN3 over night. The void volume was calculated by blue 
dextrane. 30x concentrated cell culture supernatant was mixed with glycerine (900µl 
supernatant + 100µl glycerine) and loaded onto the column. Fractions of 3ml each were 
collected, of which 2ml were used for adhesion assays and 1ml was concentrated by TCA-
precipitation and subjected to SDS-PAGE analysis.  
 
4.2.4.10 Ultracentrifugation of cell culture supernatant  
 Cell culture supernatants were centrifuged at 100000g over night at 4°C in a Beckman 
Coulter ‘Optima LE-80K’ ultracentrifuge using a SW-41 rotor. The supernatant was 
transferred and precipitated material was washed with RPMI, centrifuged again for 1h and 
resuspended in RPMI medium. Supernatant and resuspended pellet was used for coating 24-
well plates or subjected to SDS-PAGE.  
 
4.2.4.11 TCA-precipitation of proteins 
To concentrate protein in solution, proteins were precipitated with trichloric acid 
(TCA) at a final concentration of 5% (w/v) for 5min at 65°C and cooled on ice. After 
centrifugation (12000g, 30min, 4°C) the pellet was resuspended in gel loading buffer and 
subjected to SDS-PAGE.  
 
4.2.4.12 Analysis of proteins by mass spectrometry  
Protein gels were stained with Colloidal Coomassie as described. Proteins of interest 
were cut out with a scalpel. Subsequent preparations and mass spectrometrical analysis was 
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carried out at the central service of the DKFZ by MALDI-analysis (matrix assisted laser 
desorption/ionisation) using a ‘Reflex II time-of-flight’ mass spectrometer (Bruker-Daltonics 
GmbH, Bremen).  
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 Abbreviations 
 
APC   allophycocyanin 
APS   ammoniumpersulfate 
AS   BSp73AS, rat pancreatic adenocarcinoma 
ASML   BSp73ASML, rat pancreatic adenocarcinoma 
bFGF   basic fibroblast growth factor 
bp   base pair 
BSA   bovine serum albumin 
CAM   cell adhesion molecule 
CD44s   CD44- standard isoform  
CD44v   CD44- variant isoform 
cDNA   complementary DNA 
Da   Dalton 
DEPC   diethylpyrocarbonate 
DISC   death inducing signaling complex 
DKFZ   ‚Deutsches Krebsforschungszentrum’ 
DMSO   dimethylsulfoxide 
DNA   desoxyribonucleic acid 
DTT   dithiothreitole 
E. coli   Escherichia coli 
ECL   enhanced chemiluminescence 
EDTA   ethylendiamintetra acetic acid 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
EpCAM   epithelial cell adhesion molecule 
ECM   extra cellular matrix 
ERK   extracellular regulated kinase 
pERK   phosphorylated ERK 
FACS   fluorescence-activated cell sorter 
FCS    fetal calve serum 
Fig.   Figure 
FITC   fluorescein isothiocyanate 
g    gram 
g    gravitational acceleration 
G418   geneticine 
GFP   green fluorescence protein 
Gy   Gray 
h   hour 
H20d   distilled water 
HA    hyaluronic acid 
HEPES   N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic acid  
HGF   hepatocyte growth factor 
HGFR   hepatocyte growth factor receptor (c-met) 
HRP   horseradish peroxidase 
hygro   hygromycine 
ifp   intra-footpad 
Ig    immune globulin 
IP    immuno precipitation 
i.v.   intra-venous 
Abbreviations 
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l   litre 
k.d.   knock down 
LB-medium  Luria-Bertani-medium 
m   milli 
µ   mikro 
M   molar 
MAPK   mitogen activated protein kinase 
min   minute 
MMP   matrixmetalloprotease 
N-CAM  neural cell adhesion molecule 
neo   neomycine 
PBS   phosphate buffered saline  
PCR    polymerase chain reaction 
PE   phycoerythrine 
PFA   paraformaldehyde 
PI3K   phosphatidylinositol 3-kinase 
PKC    protein kinase C 
PMSF   phenylmethylsulfonylfluoride 
POD    peroxidase 
PVDF    polyvinylidenfluoride 
Rb   retinoblastome 
RNA   ribonucleic acid 
RT   room temperature 
s   second 
ss   single stranded 
ds   double stranded 
SDS   sodium dodecyl sulfate 
SDS-PAGE   SDS-poly-acrylamid-gelelectrophorese 
siRNA   small interfering RNA 
shRNA  short hairpin RNA 
Tab.   Table 
TCA   trichloric acid 
TEMED  N,N,N`,N´,-tetramethylethylendiamine 
TGF-β   transforming growth factor-β 
TIMP   tissue inhibitor of metalloproteases 
TRIS   Tris(hydroxymethyl)aminoethane 
TX-100  TritonX-100 
TxRed   Texas Red 
uPA   urokinase-type plasminogen activator  
UTR   untranslated region 
V    Volt 
VEGF   vascular endothelial growth factor 
v/v    volume/volume 
WB   western blot 
wt   wildtype 
w/v    weight/vol
